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Abstract: BACKGROUND 
Many people with human immunodeficiency virus (HIV) are undiagnosed. Early diagnosis saves lives 
and reduces onward transmission. 
 
METHODS 
In a cluster randomised controlled trial in east London, 40 of 45 (89%) general practices were 
randomised and either trained to offer opt-out rapid HIV testing to newly registering adults, or 
continued usual care. The primary outcome was CD4 count at diagnosis. 
 
FINDINGS  
During the study 44,971 adults registered with 20 intervention practices, and 38,464 with 20 controls. 
Intervention practices newly diagnosed 32 people with HIV compared with 14 in control; rate of HIV 
diagnosis was fourfold higher in intervention than control practices: 0*30 per 10,000 patients per year 
(95% CI, 0*11 to 0*85) versus 0*07 (95% CI, 0*02 to 0*20); adjusted ratio of geometric means: 4*51 
(95% CI, 1*27 to 16*05; P=0*021). Mean CD4 count at diagnosis was 356 cells/μL (SD 254) 
intervention versus 270 (SD 257) control; adjusted difference in square root CD4 count: 3*1 (95% 
confidence interval [CI], -1*2 to 7*4; P=0*16); in a pre-planned sensitivity analysis excluding patients 
diagnosed via antenatal care, this difference was 6*4 (95% CI, 1*2 to 11*6; P=0*017). All people 
diagnosed via rapid testing were successfully transferred into specialist care. 
 
INTERPRETATION 
Promoting opt-out rapid testing in general practice led to increased and earlier detection of HIV. 
  
FUNDING 
Department of Health, NHS City and Hackney; (ClinicalTrials.gov: ISRCTN63473710). 
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Summary 
BACKGROUND 
Many people with human immunodeficiency virus (HIV) are undiagnosed. Early diagnosis 
saves lives and reduces onward transmission. We tested the hypothesis that an education 
programme promoting rapid HIV testing in general practice would lead to increased and 
earlier HIV diagnosis. 
METHODS 
In a cluster randomised controlled trial in east London, 40 of 45 (89%) general practices were 
randomised and either trained to offer opt-out rapid HIV testing to newly registering adults, 
or continued usual care. The primary outcome was CD4 count at diagnosis. 
FINDINGS  
During the study 44,971 adults registered with 20 intervention practices, and 38,464 with 20 
controls. Intervention practices newly diagnosed 32 people with HIV compared with 14 in 
control; rate of HIV diagnosis was fourfold higher in intervention than control practices: 0·30 
per 10,000 patients per year (95% CI, 0·11 to 0·85) versus 0·07 (95% CI, 0·02 to 0·20); 
adjusted ratio of geometric means: 4·51 (95% CI, 1·27 to 16·05; P=0·021). Mean CD4 count 
at diagnosis was 356 cells/µL (SD 254) intervention versus 270 (SD 257) control; adjusted 
difference in square root CD4 count: 3·1 (95% confidence interval [CI], -1·2 to 7·4; P=0·16); 
in a pre-planned sensitivity analysis excluding patients diagnosed via antenatal care, this 
difference was 6·4 (95% CI, 1·2 to 11·6; P=0·017). All people diagnosed via rapid testing 
were successfully transferred into specialist care. 
INTERPRETATION 
Promoting opt-out rapid testing in general practice led to increased and earlier detection of 
HIV.  
FUNDING 
Department of Health, NHS City and Hackney; (ClinicalTrials.gov: ISRCTN63473710). 
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Introduction 
Timely diagnosis of HIV remains a major challenge. Undetected HIV and late diagnosis are 
associated with ill health, increased risk of death and onward viral transmission, constituting 
a significant burden to public health budgets worldwide.1-3 Of 107,800 people living with 
HIV (PLHIV) in the UK, almost one quarter are undiagnosed,4 42% are diagnosed late (after 
they should have begun antiretroviral treatment, CD4<350), and 24% diagnosed very late 
(CD4<200).4 These figures are mirrored in the WHO European Region and the USA, where 
an estimated one half of 2·2 million, and one sixth of 1·1 million PLHIV respectively, are 
undiagnosed. 2,5,6  
Expanding HIV testing is key to improving HIV outcomes, however evidence on outcomes 
from robust screening trials is lacking. The US Preventative Services Task Force recently 
noted: ‘no randomised trial or observational study compared clinical outcomes between 
adults and adolescents screened and not screened for HIV infection,7 a conclusion also 
reached by the UK National Institute for Health and Care Excellence.8,9 To our knowledge, 
there is no randomised trial evidence that HIV screening leads to increased and earlier 
diagnosis. This represents a key evidence gap in current guidance.10,11  
Primary care is ideally placed to offer HIV testing.12 General practices provide health checks 
for newly registering patients and are a referral point to specialist care. HIV testing in general 
practice is feasible and acceptable,13-15 and may be preferable for people who would not 
normally attend traditional HIV testing settings such as sexual health clinics.15  
We report on a pragmatic cluster randomised controlled trial (RCT) to test the hypothesis that 
a multifaceted educational outreach programme promoting rapid HIV testing in general 
practice leads to increased and early diagnosis of HIV. We used a cluster randomised design 
because the intervention was directed at practices, rather than individual patients. 
PANEL – Research in context – about here 
Methods 
The study was set in Hackney, a multi-ethnic, socioeconomically deprived inner London 
borough with a rate of diagnosed HIV infection of 8/1000 adults. Forty of 45 (89%) general 
practices in Hackney enrolled by the study team were cluster randomised to the HIV testing 
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programme or usual care. There were no exclusion criteria for clusters. Consent from 
participating practices was sought before randomisation. 
The study was approved by Camden and Islington Community Research Ethics Committee 
(09/H0722/67). An independent data monitoring committee (DMC) was established.  
Randomization of general practices and masking 
Practices were randomised between April 2010 and August 2011 by an independent clinical 
trials unit statistician using a minimisation program (Minim, v1·3),16 maintaining allocation 
concealment. Minimisation criteria were: practice list size (<5,000 registered patients; 5,000-
7000; ≥7,000); practice deprivation (Index of Multiple Deprivation score:<47; ≥47);17 and 
male HIV testing rate (male adults tested between April and October 2009/adults registered 
x1000: <7; ≥7). The nature of the intervention meant that neither investigators nor clinical 
teams were masked to allocation. 
Inclusion criteria for eligible patients 
Patients aged 16 years and older, who newly registered with study practices and were able to 
undertake a pre−test discussion in English, or with a suitable translator, were included. 
Patient consent for study participation  
Patient information sheets, available in English and eight locally spoken languages, were 
displayed at reception desks. The ethics committee approved a process of valid implied 
consent for patient participation.16  
Intervention 
The intervention was multifaceted and comprised:  
• a practice-based outreach educational program, with follow up training for a 
nominated practice HIV lead nurse or health care assistant (HCA); 
• integration of rapid HIV testing into the registration health check and management of 
reactive tests; 
• provision of free rapid HIV tests and payment of £10 ($16·14) per test completed; 
• Quality assurance testing programme. 
Practice-based outreach educational programme for intervention practices 
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The educational programme was based on proven theory-based clinician behaviour change 
strategies from the literature together with our experience of delivering similar effective 
interventions.18-20 Initial training sessions were held at individual practices, lasted 90 minutes, 
targeted the whole practice team, and included didactic and interactive elements. Session 
leaders (WL, HM) were trained to ensure intervention fidelity (Supplement A). Rapid HIV 
test operators completed competency-based training. An HIV lead was nominated in each 
practice to co-ordinate rapid testing and quality assurance (Supplement B). 
Integrating rapid HIV testing into the registration health check, management of 
reactive tests and confirmatory serology testing 
Registration health checks are performed by a nurse or HCA, who follow prompts on a 
template in the patient’s electronic health record. We inserted additional prompts to offer 
rapid HIV testing, linked to bespoke Read codes (http://www.hscic.gov.uk/) to record test 
outcomes: non-reactive, reactive, indeterminate, invalid, and test declined. Read coding 
enabled remote data collection of testing activity (Supplement C). 
The intervention was adaptable to each individual practice: e.g. staff could additionally offer 
rapid HIV testing in a range of clinical settings (e.g. sexual health checks) and were 
encouraged to continue opportunistic HIV testing by serology. 
The core components of the testing process included:  
• an offer of a rapid HIV test to eligible patients including a pre-test discussion for them 
to make an informed decision regarding the HIV testing; 
• a rapid HIV test followed by a post-test discussion for patients with a non-reactive 
test result;  
• an immediate notification of the rapid test operator to the general practitioner (GP) of 
any patient with a reactive/indeterminate/twice invalid test result with confirmatory 
serology sampling, and follow up by a GP (Supplement D).  
Patients confirmed HIV1/HIV2 antibody positive (Supplement E) were referred to Homerton 
Hospital for specialist care. Practices implemented rapid testing immediately after the 
educational session. Ongoing support from the education team was available to practice staff 
for queries related to rapid testing via telephone or email.  
Control practices 
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Control practices were informed by email about current national guidance on HIV testing.  
All study practices continued to provide standard care of HIV testing and were supported by 
a community HIV liaison nurse.  
Primary and secondary outcomes 
Early and increased diagnosis of HIV are key clinical and public health outcomes.4,8,9,12 
The primary outcome measure was the mean CD4 count at diagnosis of newly diagnosed 
patients. Women newly diagnosed with HIV by the UK Antenatal HIV Screening Programme 
were included. For exclusion criteria for the primary outcome and definition of a newly 
diagnosed patient, see Supplement F. 
Secondary outcome measures were number of new HIV diagnoses (expressed as rate: 
patients diagnosed/year/10,000 practice list size), and percentages of patients with CD4<350 
and CD4<200. 
The original primary outcome for the study was the number of new HIV diagnoses. However, 
our initial assumptions were based on limited data and the number of new diagnoses early in 
the study was lower than expected. Thus, early in the trial, and with the approval of the data 
monitoring committee, we recalculated statistical power with CD4 count as the primary 
outcome, retaining numbers of new diagnoses as the main secondary outcome. For clarity we 
report both outcomes.  
Patients newly diagnosed with HIV in general practice, data extraction and validation 
At Homerton Hospital, all patients testing HIV positive at participating practices were 
allocated a unique study number. Newly diagnosed patients were distinguished from known 
HIV positive patients already in care or defaulted from specialist care using the Genitourinary 
Medicine Clinical Activity Dataset.21 The Homerton clinical team (JA, SM) extracted clinical 
record data onto anonymised confidential clinical case report forms. Accuracy of data 
extraction for all patients was verified by an independent clinician (AM), blinded to study 
allocation, before being passed to the study statistician. For more details on patient 
ascertainment, see Supplement G. 
Study power  
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Allowing for clustering, and assuming 20 practices in each arm and analysis of CD4 on the 
square root scale with a SD of 6 and ICC of 0·05, we expected to identify 72 new HIV 
diagnoses and, with 80% power and 5% significance. This would be sufficient to detect an 
increase in the mean CD4 count from 300 to 470 cells/µL, corresponding to a reduction in the 
proportion of late presenters from 30% to 10%. Allowance was made for practices to identify 
variable numbers of patients or none at all.22  
Analysis 
Intervention effect on CD4 count and rate of diagnosis was estimated using a regression 
model adjusted for clustering in Stata (v12) using the cluster option (except for rate of 
diagnosis where practice summary data was used) and adjusted for minimisation factors. CD4 
count was transformed using a square root transformation and rate of diagnosis was log 
transformed after adding 0·01 to zero counts. We estimated the relative reduction in the 
percentage of patients diagnosed with both CD4<350 and CD4<200 cells/µL, using the 
normal distribution.23 
Sensitivity analyses 
The UK Antenatal HIV Screening Programme offers all women in antenatal care an HIV test. 
We carried out a pre-planned a sensitivity analysis excluding women diagnosed via this 
programme.  
Some patients testing positive had previously been diagnosed but had defaulted from 
specialist care: ‘re-diagnosis’ in general practice therefore led to re-entry to specialist care. A 
further sensitivity analysis therefore included those testing positive who had defaulted from 
care. 
Role of the funding source 
NHS Hackney and the Department of Health funded the study; they had no role in the 
analysis. 
Results 
General practices and populations 
Forty of 45 (89%) general practices agreed to take part; and five declined (Figure 1). Twenty 
practices were randomised to intervention and 20 to the control group. Three intervention 
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practices withdrew during the study (one stopped offering registration health checks; one for 
workload reasons; and one closed, but all provided complete study data and were included in 
the analysis. Practice and population characteristics and numbers of newly registering 
patients were well balanced after randomisation (Tables 1a and 1b). The study began in April 
2010, and ended in August 2012 when funding expired. 
Intervention practices offered 11,187 rapid tests, of which 4,978 (44.5%) were accepted 
(Table 2). Of these, 4,964 were not reactive and 14 were reactive, including 11 that were 
confirmed HIV positive (true reactive) and three confirmed HIV negative (false reactive). 
INSERT FIGURE 1 (Flow chart) here 
INSERT TABLE 1a and 1b (Practice and patient characteristics) here 
INSERT TABLE 2 (HIV tests and diagnoses) here 
INSERT TABLE 3 (CD4 counts) here  
Overall, intervention practices identified 43 HIV positive patients, of whom 11 had 
previously been diagnosed, giving a total of 32 new HIV diagnoses, 11 of which were 
diagnosed by rapid testing. Control practices identified 21 HIV positive patients, of which 
seven had previously been diagnosed, giving a total of 14 new HIV diagnoses (Figure 1). 
The UK Antenatal Screening Programme led to three new HIV diagnoses in intervention 
practices and four in controls.  
Of the 32 new diagnoses in the intervention group, 19 (59%) were men, 20 (63%) were of 
black African origin, and six (16%) were men who have sex with men (MSM). 
Primary outcome: CD4 count at diagnosis 
CD4 count data were available in 30 of the 32 newly diagnosed patients from intervention 
practices, and in all 14 patients from controls. The mean CD4 count in intervention practices 
was higher compared to control: 356/µL (SD 254), and 270/µL (SD 257) respectively, but not 
significantly so; (adjusted difference in square root transformed CD4: 3·1; 95% confidence 
interval [CI], -1·2 to 7·4; P=0·16, Table 3).  Two pre-planned sensitivity analyses showed 
that the effect of the intervention on CD4 count was significantly greater when patients 
diagnosed via the UK antenatal HIV screening program were excluded (6·4; 95% CI, 1·2 to 
11·6; P0·017, Table 3), and when patients who had been previously diagnosed with HIV but 
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defaulted from care were included in the analysis (4·1; 95% CI, 0·0 to 8·1; P=0·049, Table 
3). 
Secondary outcomes 
Rate of new HIV diagnoses 
Rate of HIV diagnosis was fourfold higher in intervention than control practices: with 0·30 
(95% CI, 0·11 to 0·85) per 10,000 patients per year in the intervention, and 0·07 (95% CI, 
0·02 to 0·20) in the control arm; (adjusted ratio of geometric means: 4·51; 95% CI, 1·27 to 
16·05; P=0·021, Table 2). In a sensitivity analysis, the effect of intervention on rates of 
diagnoses was similar in all population subgroups (Table 2). 
Proportions of diagnoses with CD4 counts <350, and <200 cells/µL 
We estimated that 73% of control patients had a CD4 count less than 350 cells/µL, compared 
with 55% of intervention patients; (risk ratio 0·75, 0·53 to 1·07). Corresponding figures for 
CD4 less than 200 cells/µL were 46% versus 28%; (risk ratio 0·60, 0·32 to 1·13). 
Discussion 
Summary 
We demonstrate that an educational outreach programme promoting opt-out rapid HIV 
testing of people newly registering in general practice leads to increased and earlier diagnosis 
of HIV. These are key goals of HIV-focussed clinical and public health programmes. Effects 
were more strongly significant in sensitivity analyses excluding women diagnosed through 
the UK’s existing antenatal HIV screening programme. Practices used both rapid and 
opportunistic serology testing to make new diagnoses. A high proportion (62%) of newly 
diagnosed patients were of Black African origin, reflecting successful integration of testing 
into a multi-ethnic community, recognised as a hard to reach population.24 To our knowledge 
this is the first randomised trial to demonstrate improvements in clinical outcomes from HIV 
screening.  
Strengths and weaknesses 
Strengths of our study included a pragmatic ‘real world’ design that included almost all 
practices (89%) in the borough, improving generalisability of our findings. Randomisation 
was robust, maintaining allocation concealment. Analysis was by cluster at the level of 
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general practices. Remote searching of practice computer systems ensured consistent data 
capture of testing activity and outcomes across practices. Access to test results from the 
regional laboratory ensured complete capture of all positive tests, minimising detection bias. 
The Public Health England national surveillance system allowed accurate distinction between 
patients newly diagnosed in primary care from those who had previously tested positive. 
Validation of data extraction by an independent clinician, blinded to allocation, of all newly 
diagnosed patients ensured accuracy and completeness of primary and secondary outcomes. 
Our multi-faceted intervention was based on a previously successful screening intervention 
for tuberculosis in general practice,18 which used a variety of effective behaviour change 
techniques. The effectiveness of outreach visits, and clinician education combining mixed 
didactic and interactive elements, is well established.25 Computer prompts to testing and 
incentive fees may also have enhanced behaviour change.26 A quality assurance scheme, 
which included competency-based training for rapid HIV testing, regular electronic 
monitoring of point-of-care results and bi-monthly assessment of staff using external control 
serum samples, enhanced patient safety by reducing the chances of false positive rapid test 
results. All patients diagnosed via rapid testing were successfully transferred to secondary 
care indicating that the links we established between general practice and specialist services 
were safe and effective. Some patients who had defaulted specialist care re-entered specialist 
services following a ‘re-diagnosis’ by their GP, suggesting that primary care can play an 
important role in maintaining the patient care continuum. 
A weakness was that three intervention practices discontinued testing. These discontinuations 
reflect the pragmatic real world study design. We were, nonetheless, able to include complete 
data from all practices in the analysis. Registration health checks are optional, thus only those 
that attend (about 50% of all registering patients) can be offered a test. Increasing attendance 
at checks would increase the impact of our intervention. Whilst it was impossible to blind 
clinical and research teams to allocation, validation of data extraction by a blinded 
independent clinician helped ensure validity of study data.  
Comparison with previous research 
Observational studies suggest that targeted community-based approaches to HIV testing 
achieved high uptake, and a higher proportion of cases with CD4 count at diagnosis >350.27 
In community centres in the USA, nurse-initiated routine universal non-targeted rapid HIV 
testing achieved similar uptake and yields of new diagnoses to those seen in the current 
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study.28 Nurse-initiated rapid testing with streamlined counselling in primary care is feasible 
compared to traditional approaches.28,29 These observations lend credibility to our findings.  
Clinical and research implications 
Our findings provide the strongest evidence yet that HIV screening in primary care leads to 
increased and earlier HIV diagnosis. This finding addresses a key gap in the evidence base 
for HIV testing, lending randomised evidence in support of guideline recommendations.  
Our results justify renewed efforts to implement community screening for HIV. This study 
builds on our previous work showing screening for tuberculosis is effective in primary care.18 
Screening for multiple infectious agents in at-risk populations seems justifiable.  
Conclusion 
Our findings provide robust high quality evidence to support HIV screening programmes in 
primary care to reduce undiagnosed and late diagnosed infection in high prevalence settings. 
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PANEL - Research in context 
Evidence before this study: 
We searched PubMed for randomised controlled trials, from year 2000 to 2009, testing the 
effects of screening for HIV in primary care on rate of HIV diagnosis and stage of 
diagnosis, according to the following PICO: 
Populations:  Adults 
Interventions: HIV screening and HIV testing interventions 
Comparator:  Randomized controlled trials with usual care as a comparator 
Outcomes:  Rate of HIV diagnosis; CD4 count; HIV stage of diagnosis 
We found no studies that met these criteria. 
A similar search was carried out in 2011 by the US Preventative Services Task Force as 
part of their evidence review to update the 2005 U.S. Preventive Services Task Force 
recommendations on HIV screening. They noted: ‘no randomised trial or observational 
study compared clinical outcomes between adults and adolescents screened and not 
screened for HIV infection’ 
Added value: 
These findings provide, to our knowledge, the first robust randomised evidence that a 
screening programme leads to increased and early HIV diagnosis 
Implications:  
Public Health leads should consider implementing primary care based screening for HIV 
in high prevalence areas 
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Figure 1. Flow of clusters and trial arm specific data. 
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20 practices
96,500 registered patients
Follow up
20 practices
44,971 newly registered patients
Follow up
20 practices
38,464 newly registered patients
Patients tested
4,978 using rapid HIV testing
2,728 by serology
Patients tested
0 using rapid HIV testing
2,465 by serology
Patients testing positive for HIV
43 patients
Patients testing positive for HIV
21 patients
Primary analysis
32 patients
diagnosed in 14 practices
Primary analysis
14 patients
diagnosed in 8 practices
Known HIV positive
11 patients
7 retained in care
4 defaulted from care
Known HIV positive
7 patients
5 retained in care
2 defaulted from care
Figure 1
Table 1a. Baseline characteristics of participating clusters (general practices) according to 
minimisation factors and registered patients.!!
!
 
* The male HIV testing rate is defined as the number of male adults tested between April and October 
2009/adults registered x1000. 
 
!
Characteristic Intervention practices (N=20) Control practices (N=20) 
Practice factors at baseline 
List size – no. of practices (%) 
   Low (<5000) 
   Medium (5000-7000) 
   High (≥7000) 
8 (40%) 
5 (25%) 
7 (35%) 
8 (40%) 
5 (25%) 
7 (35%) 
HIV testing rate in males* 
   Low (<7) 
   High (≥7) 
13 (65%) 
7 (35%) 
13 (65%) 
7 (35%) 
Index of multiple deprivation score 
   Low (<47) 
   High (≥47) 
11 (55%) 
9 (45%) 
10 (50%) 
10 (50%) 
Patient factors at baseline 
Number of registered patients 99,670 96,500 
Age (range) 
   16-24 – no. (%) 15,623 (15!7%) 13,198 (13!7%) 
   25-34 – no. (%) 28,200 (28!3%) 29,292 (30!4%) 
   35-49 – no. (%) 31,218 (31!3%) 31,990 (33!2%) 
   >50 – no. (%) 24,629 (24!7%) 22,020 (22!8%) 
Male sex – no. (%) 50,224 (50!4%) 48,929 (50!7%) 
Ethnicity – no. (%) 
   White 
   Black 
   Asian 
   Mixed 
   Other  
   Unknown 
40,250 (40!4%) 
20,467 (20!5%) 
8,487 (8!5%) 
3,396 (3!4%) 
7,134 (7!2%) 
19,934 (20!0%) 
48,262 (50!0%) 
17,690 (18!3%) 
8,002 (8!3%) 
4,207 (4!4%) 
3,562 (3!7%) 
14,777 (15!3%) 
Table 1a
Table 1b: Characteristics of newly registering patients. 
!
The percentages may not total 100 due to rounding. 
 
Characteristic Intervention practices (N=20) Control practices (N=20) 
Total number of new registrants 44,971 38,464 
Number of new registrants per practice – median (range) 1,379 (150-7830) 1,802 (280-4039) 
Age (range) 
   16-24 -  no. yr (%) 
   25-34 -  no. yr (%) 
   35-49 -  no. yr (%) 
   >50  -  no. yr (%) 
7,667 (17!0%) 
19,491 (43!3%) 
10,950 (24!3%) 
6,863 (15!3%) 
6,207 (16!1%) 
18,170 (47!2%) 
9,016 (23!4%) 
5,071 (13!2%) 
Male sex - no. (%) 20,219 (45!0%) 17,119 (44!5%) 
Ethnicity – no. (%) 
   White 
   Black 
   Asian 
   Mixed 
   Other 
   Unknown 
23,947 (53!2%) 
6,400 (14!2%) 
3,472 (7!7%) 
1,296 (2!9%) 
2,066 (4!6%) 
7,790 (17!3%) 
22,365 (58!1%) 
5,253 (13!7%) 
3,011 (7!8%) 
1,442 (3!7%) 
1,389 (3!6%) 
5,004 (13!0%) 
Table 1b
Table 2. HIV testing and diagnoses.  
 
a Calculated as geometric mean of rates for each practice 
b Calculated as ratio of geometric means. 
Characteristic Intervention practices  (N=20) Control practices (N=20) Ratio of rates of 
diagnosisb (95% 
CI)
Numbers of 
patients
Rate of diagnosis 
per 10,000 
registered patients 
per yeara
Numbers of 
patients
Rate of diagnosis 
per 10,000 
registered patients 
per yeara
HIV testing
Total number of new registrants
Number of patients offered rapid tests
Number of patients accepting rapid tests
Number of patients with NOT reactive rapid tests
Number of patients with reactive tests
Number of patients confirmed HIV positive
Number of patients with serology test performed
44,971
11,187 (24·9%)
4,978 (44·5%)
4,964 (99·7%)
14
11
2,728
38,464
NA
NA
NA
NA
NA
2,465
HIV diagnoses
Total number of diagnoses (new and previously 
diagnosed)
43 21
New HIV diagnoses
Rapid testing
Opportunistic testing
Antenatal screening program
32
11
18
3
0·30 [0·11,0·85] 14
NA
10
4
0·07 [0·02,0·20] 4·51 [1·27,16·05]
Previously diagnosed with HIV
Previously diagnosed patients defaulted from care
Previously diagnosed patients retained in care
11
4
7
7
2
5
Sensitivity analysis
All new diagnoses excluding antenatal
All new diagnoses plus those defaulted from care
29
36
0·23 [0·07,0·70]
0·32 [0·11,0·91]
10
16
0·04 [0·01,0·11]
0·07 [0·02,0·21]
5·88 [1·71,20·17]
4·53 [1·25,16·38]
Table 2
Table 3.  CD4 count of newly diagnosed patients in intervention and control practices.  
 
a Calculated from square root of CD4 count 
* CD4 count unavailable in 2 patients. 
 
 
Characteristic Intervention practices (N=20) Control practices (N=20) Difference 
adjusted for 
minimisation 
factorsa
(95% CI)
Number of 
patients
CD4 count
Mean (SD)
Square root 
of CD4 
count
Mean (SD)
Number of 
patients
CD4 count
Mean (SD)
Square root 
of CD4 
count
Mean (SD)
New diagnoses 32* 356 (254) 17·7 (6·6) 14 270 (257) 14·7 (7·7) 3·1 [-1·2,7·4]
All new diagnoses 
excluding antenatal
29* 369 (262) 18·0 (6·7) 10 194 (169) 12·4 (6·7) 6·4 [1·2,11·6]
All new diagnoses plus
those defaulted from care
36* 411 (288) 19·0 (7·2) 16 259 (242) 14·5 (7·3) 4·1 [0·0, 8·1]
Table 3
Supplement 
Supplement part A: Practice based educational program for intervention 
practices 
The GP educational outreach program comprised two parts: the first (30 minutes), 
aimed at the whole practice team, introduced the rational for HIV testing, local 
epidemiology, trial design, and information on the safe implementation of rapid HIV 
testing; the second (60 minutes) was a competency-based practical training for rapid 
test operators only.  
This competency-based training included successful completion of rapid testing 
(INSTI HIV1/HIV2 Rapid Antibody Test, bioLytical Laboratories, Canada) on two 
different HIV-negative volunteers including a pre-test discussion and one human 
serum control sample containing HIV-1 antibody. Results were recorded on training 
record sheets. rapid test operators, who had correctly conducted an HIV pre- and post-
test discussion, adequately processed the test samples and correctly interpreted the 
test results, received a certificate of completion of training. 
Supplement part B: Practice HIV lead nurse training and quality assurance 
At the end of the educational session, each surgery was asked to nominate a surgery 
HIV lead to co-ordinate rapid HIV testing and to act as a contact point for the study 
team. The lead nurse received additional training 2-6 weeks later, comprising a follow 
up visit including instructions on supervising and co-ordinating rapid testing within 
the surgery, on the importance of follow up of patients with a reactive, indeterminate 
or twice invalid rapid test result, and on the quality assurance program.  
 
For the quality assurance program, intervention practices were sent, at two monthly 
intervals, two control serum samples by the local virology laboratory for testing at. 
They reported results to the QA manager (MS). Practices received feedback; any that 
returned incorrect results were offered further support in rapid testing. During 
alternative months, control samples containing HIV1 antibody were sent to the 
practices for internal control. Participation in internal control was optional. 
 
Supplementary material
Supplement part C: Testing activity and outcomes from study practices 
We carried out quarterly remote searches of participating practices’ computer systems 
to obtain Read coded data on rapid test outcomes and rapid tests declined. Any 
reactive/indeterminate/twice invalid test result was checked via email or phone call 
with the practice HIV lead nurse or health care assistant for its clinical relevance. 
Serology test activity was collated at the end of the study. Thirty eight practices used 
EMIS (Egton Medical Information Systems Limited, UK), and two practices used 
Vision (In Practice Systems Limited, UK) electronic medical record software.  
Supplement part D: The rapid testing process 
Pre-test discussion 
1. When offering the rapid HIV test, GP staff was advised to use the following 
phrases: 
“Is it ok if we do an HIV test? We are offering them to everyone; we’ll get the result 
within the consultation. Things have changed in HIV; it is now a treatable medical 
condition, people can have a family and children, and there are drugs available free 
for everyone and like all medical conditions it is better to pick it up in the early 
stages.” 
2. To secure confidentiality in the case of an accompanied patient, rapid test operators 
were advised to state the following: 
“For this portion of the health check, I am going to ask your guest to step outside for a 
moment”. And once the patient’s guest would have left the consultation room, the 
rapid test operator was advised to say: “I just wanted to make sure you were 
comfortable saying ‘yes’ or ‘no’ to a rapid HIV test. If you are comfortable having the 
test and receiving the result in front of your guest, I have no problem inviting them 
back in”. 
Post-test discussion 
After completion of the testing procedure and according to the test outcome, the nurse 
or health care assistant was advised to say the following to the patient: 
1. Non-reactive result 
“We did not find HIV today. If you have had any risk in the last 3 months you need to 
retest in one and three months’ time.  Recent risk means sex without condoms, 
unsterile procedures or infected blood transfusions abroad, or sharing needles.” 
2. Reactive or indeterminate result 
 “While we are awaiting the result of your HIV test would you mind taking a seat in 
the waiting room?  A GP or nurse will see you shortly.” Or: “ I am a bit unsure about 
the test result so I have asked the GP or nurse to come in and explain it to you.” 
3. Twice invalid result 
“Your rapid test result has been twice invalid.  This means that there may be some 
problem with the test device.  To be sure you are not infected, I am going to take 
some blood from your arm.” 
Specific points: 
1. Non-reactive rapid test result 
Any patient with a non-reactive rapid HIV test result but recent risk was advised to 
have a repeat rapid HIV test three months after their most recent exposure; 
confirmatory test using venous blood test was offered as an alternative one and three 
months after their most recent exposure, particularly when the patient was anxious. 
2. Reactive/indeterminate or twice invalid result 
Practices were advised that any reactive/indeterminate or twice invalid rapid test 
result be verified by another INSTI trained nurse or a GP within five minutes of 
completion of the testing procedure and that a GP or senior practice nurse undertake a 
post-test discussion with the patient. The GP was advised to share the rapid test result 
with the patient, address any immediate concerns they might have, request a venous 
blood for confirmatory testing, and arrange a follow up appointment, indicating the 
method and timing of receiving the test result to the patient. 
3. Seroconversion illness 
Patients with a non-reactive rapid test result presenting with symptoms suggestive of 
HIV seroconversion illness were offered immediate venous blood sampling. 
Alternatively, the patient was offered immediate referral to the Department of Sexual 
Health at Homerton Hospital to exclude early HIV infection.  
Supplement part E: HIV1/HIV2 confirmatory testing 
All serology samples were sent to Homerton Pathology for combined screening of 
HIV p24 antigen and HIV1/HIV2 antibody using the Abbott Architect ci8200 fourth 
generation assay. Any reactive serology specimen was sent to the Department of 
Virology, Barts Health NHS Trust, for confirmatory testing. 
Supplement part F: Exclusions and definitions 
Exclusion of patients from the primary outcome measure 
Patients in whom the GP had not performed HIV testing prior to referral, and patients 
who were referred by their GP to secondary care at Homerton Hospital either for HIV 
testing or for further management of a suspected HIV-related illness were excluded 
from the primary outcome measure.  
Definition of a newly diagnosed patient 
A newly diagnosed patient was defined as a person who was unaware of their HIV 
status at the time of testing, but who tested either HIV1 or HIV2 antibody positive 
following a GP request for HIV confirmatory testing at Homerton Pathology. 
Supplement part G: Patient ascertainment 
All those testing HIV positive were allocated a unique study number, which was used 
to send communicate anonymised data to the research team.  A confidential register 
linking study number to personal data was maintained by the clinical team at 
Homerton Hospital. No personally identifiable information was shared with the 
research team. Evidence of any prior HIV diagnosis, whether in or defaulted from 
care, was obtained from Public Health England. For each newly diagnosed patient, 
study clinicians compiled data on a clinical record form. These data were extracted 
onto a fully anonymised summary table. Accuracy of data extraction for all patients 
was checked by an independent clinician blinded to study allocation, before being 
passed to the study statistician. 
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Study Summary 
Full Title Effectiveness of HIV screening in Primary Care: a cluster 
RCT and economic analysis 
Short Title Trial of HIV Screening in Primary Care 
Protocol Version 
 
Date 
Version 5.0  
 
02 May 2012 
Methodology Cluster randomized controlled trial 
Trial Start Date 19 April 2010 
Study Duration 2 years and 4 months and 12 days 
Study Centres Queen Mary, University of London; Homerton University 
Hospital NHS Trust; Royal Free and UCL Medical School; NHS 
City and Hackney; London School of Hygiene and Tropical 
Medicine 
Primary Objective  To determine whether a targeted intervention with rapid point 
of care testing in GP surgeries leads to earlier detection of HIV 
Numbers of GP 
Surgeries invited to 
participate 
45 
Numbers of GP 
Surgeries enrolled 
to date 
40 
Number of Patients 23,000 patients (estimated) 
Main Inclusion 
Criteria 
(1) Individuals aged 16 years or older registering at study 
practices 
(2) Individuals able to undertake the pre−test discussion in 
English or with a suitable translator. 
Statistical 
Methodology and 
Analysis 
A pragmatic, cluster randomised, controlled trial across up to 
45 GP surgeries in Hackney 
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Glossary of Terms and Abbreviations 
      
 Advanced HIV infection An advanced HIV infection is defined as CD4 count lower than 
200 cells per cubic millimetre of blood. 
AIDS Acquired immunodeficiency syndrome 
BHIVA British HIV Association 
BLT Barts and The London NHS Trust 
CI Chief Investigator 
DMC Data monitoring committee 
GP General Practitioner 
HIV Human immunodeficiency virus 
PCT Primary Care Trust 
Rapid HIV test HIV test performed on a finger prick blood sample using a rapid 
point of care test device. 
Standard HIV test HIV test performed on a venous blood sample using fourth 
generation HIV assays (gold standard). 
Usual HIV care A GP practice offering a HIV test from a venous sample 
REC:09/H0722/67_RHIVA2_Trial_Protocol_v5.0_04May2012   Page 14 of 39 
 
                Confidential: this protocol may only be disseminated with the permission of the chief investigator 
1 Introduction 
1.1 Background 
HIV is a serious but treatable chronic disease affecting more than 80.000 patients in the UK, 
of who about a quarter (28%) are unaware of their infection (HPA, 2008a). Despite 
enormous public health efforts, HIV continues to spread in the community. In the year 2007 
alone, 7700 new cases of HIV were reported in the UK and nearly a third (31%) of those 
presented with advanced disease. Until recently, standard HIV care focused on testing of 
high−risk groups and of those presenting with AIDS−related conditions such as tuberculosis. 
Early detection of HIV is important to reduce unwitting onward transmission of HIV to 
partners and children, and to prevent late presentation that is associated with adverse 
outcomes, notably risk of AIDS and death. 
1.2 Rapid point of care HIV testing 
Rapid point of care (near patient) HIV testing combined with pre− and post−test counselling 
has been accepted as an important tool for the prevention and early management of HIV. 
For patients with a negative test result, rapid point of care HIV testing is a great opportunity 
for sexual health education to prevent future disease. Patients with a positive test are more 
likely to attend specialist services to receive adequate treatment and psycho−social support 
for both the individuals affected and their families. 
In East London, rapid HIV testing is being offered routinely on an ‘opt−out’ basis to risk 
groups in sexual health clinics, charities and community programs. It is now commonly 
believed that the widening of access to rapid HIV testing in GP surgeries in Hackney would 
promote both prevention and identification of HIV infection. New expert guidelines recently 
published by the British HIV Association (BHIVA) recommend universal opt−out HIV testing 
in Primary Care in areas where two or more people per 1000 are infected with HIV (BHIVA, 
2008). Estimates based on unlinked anonymous data indicate that the numbers for Hackney 
are four times as high (8 per 1000) (HPA, 2008b). In addition, we have recently 
demonstrated in a pilot study that rapid point of care HIV testing performed during the new 
patient health check in a single GP surgery in Hackney was welcomed and accepted by 
patients and achieved an uptake of 45% (Prost et al., 2009). 
1.3 Rationale and risk/benefit assessment 
For the reasons given above, data from clinical trials evaluating the feasibility of large-scale 
rapid HIV testing are timely to inform the ongoing implementation of testing guidelines in 
Primary Care. More specifically, expansion of rapid point of care HIV testing across a large 
number of surgeries has the potential to: (1) demonstrate an increase in the proportion of 
cases that are diagnosed early to reduce unwitting onward transmission of the virus, to 
prevent medical complications and to lower socio−economic costs associated with late (2)  
to demonstrate an increase in the rate of patients being tested and diagnosed with HIV and 
(3) normalise and de−stigmatise HIV by strengthening the central role of General Practice in 
diagnosing and preventing the disease. 
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2 Study Aims and Objectives 
The primary objective is to demonstrate that rapid HIV testing offered in the new patient 
health check or at first consultation, when combined with an educational package for health 
care professionals, reduces the proportion of newly diagnosed patients who present with 
advanced HIV infection from 30% to 10%. An advanced HIV infection is defined as CD4 
count lower than 200 cells per cubic millimetre of blood. This is estimated from the mean 
CD4 count, using the Normal distribution. 
 
The secondary objectives are to demonstrate (1) an increase in proportion of new HIV cases 
that qualify for the start of antiretroviral therapy, defined as a CD4 count less than 350 cells 
per cubic millimetre of blood (this will also be estimated from the mean CD4 count) (2) an 
increase in proportion of patients newly diagnosed in general practice (3) an increase in the 
rate of standard HIV tests performed opportunistically (4) a reduction in proportion of HIV 
cases with a high risk of progression to AIDS, defined as a viral load of higher than 200,000 
copies per million peripheral mononuclear cells and (5) a reduction in financial and economic 
costs incurred to the PCT. 
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3 Investigational Plan 
3.1  Overall design 
Pragmatic, cluster randomised, controlled trial 
3.2 Schema for intervention surgeries 
 
-2 
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-1 
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day 
+2 
days 
+14 
days 
 
  
Registration 
with GP 
Registration 
health check 
 
Randomisation of 
practices 
X     
Education of intervention 
practices 
 X    
Patient recruitment   X   
Valid implied consent   X   
HIV pre-test counselling    X  
Rapid HIV test    X  
Blood sample for 
confirmatory HIV test 
   X  
GP visit of rapid HIV 
positives 
   X  
GP referral to specialist 
rapid HIV positives 
   X  
Written informed consent 
confirmed HIV positives 
    X 
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3.3 Overview of study population 
The study population will comprise all patients aged 16 years and older registering with a GP 
surgery in Hackney, who fulfil the eligibility criteria stated in section 4 of this protocol. 
3.4 Target accrual 
Target accrual is (1) all surgeries in Hackney and (2) 23,000 participants. 
4 GP Surgery Selection 
All GP surgeries in Hackney will be invited to take part. 
5 Subject Selection 
5.1 Inclusion criteria 
(1) Individuals aged 16 years or older registering at study practices 
(2) Individuals able to undertake the pre−test discussion in English or with a suitable 
translator. 
5.2 Exclusion criteria 
(1) Age under 16 years 
(2) Individuals with limited English abilities, who are unable to understand the info sheet or, 
who are unable to engage with the pre−test discussion for HIV testing 
(3) Known HIV positive patients. 
6 Study Procedures and Schedule of Assessments 
6.1 Recruitment of GP surgeries 
Participating surgeries will be randomised into two groups: (1) An intervention group offering 
rapid point of care HIV testing during GP registration in addition to providing routine (usual) 
HIV care and a (2) control group providing usual HIV care only. Usual care means that a 
practice GP would offer a HIV test from a venous sample upon patient request or if it is 
clinically indicated. 
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6.2 Randomisation procedures 
Practice will be randomised using a computer generated minimisation, by: 1) practice list 
size 2) practice deprivation and 3) HIV male testing rate per surgery. 
6.3 Formative phase for GP practice staff 
6.3.1 Intervention surgeries 
The formative phase for intervention surgeries will include the following: 
6.3.1.1 Analysis of the educational requirements for GPs nurses and health care 
assistants. 
6.3.1.2 Provision of training in performing the rapid point of care HIV test. 
6.3.1.3. Setting up the operating procedure for HIV testing as an integrated part of the new 
patient health check.  
6.3.1.4 Confirmation of referral pathways for newly diagnosed patients into specialist care. 
6.3.1.5 Establishing the role of the HIV liaison nurse as the key figure to facilitate 
communication about newly diagnosed patients between clinicians including GPs and the 
HIV specialist team, the Virology lab and the researchers. 
6.3.1.6 Establishing the role of the HIV point of care test co-ordinator, a member of the 
RHIVA 2 research team, as the first point of call for all technical problems related to using 
the test devices. 
6.3.2 Control surgeries 
Control surgeries will be informed about the most recent specialist recommendations for HIV 
testing and receive support from the HIV liaison nurse throughout the study period. 
6.4 Patient consent procedures 
6.4.1 Valid implied consent for registering patients. 
6.4.1.1 Valid implied consent for participation in the study will be obtained in identical 
fashion to our recent tuberculosis screening trial (Griffiths et al., 2007). Briefly, during 
registration, the practice reception will provide patients with a laminated information sheet 
available in multiple languages (see Attachments 1 and 2). Spare copies of the information 
sheet will be obtainable at the surgery for patients to take home. The sheet details 
information that the practice is taking part in a study, which compares the delivery of routine 
clinical care in two different ways: either usual care (control) or through an extended new 
patient health check that includes a rapid HIV screening test for those that would like to be 
tested (intervention).  
6.4.1.2 Most patients will be given a minimum of two days to consider whether they wish 
to participate in the study. In addition, surgeries will have the additional option of handing out 
the patient information sheets immediately prior to the testing procedure. Before offering the 
test, the rapid test operator will check that the patient has read and understood the patient 
information sheet. 
6.4.1.3 During the extended new patient health check in intervention surgeries, a suitably 
trained health care assistant or nurse will offer the rapid HIV test to eligible patients following 
a HIV pre-test discussion. 
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6.4.1.4 Patients are completely free to refuse to enter the study or withdraw from the 
study at any time and without having to specify a particular reason. 
6.4.1.5 Patients will be reminded that ‘opportunistic’ HIV testing from venous blood will 
continue to be offered at both intervention and control surgeries either upon patient request 
or if clinically indicated.  
6.4.2 Written informed consent for patients testing HIV positive 
6.4.2.1 For newly diagnosed HIV patients, we will, with written informed consent, obtain 
anonymised basic demographic data (including age, gender, ethnicity and Soundex code), 
mode of diagnosis, route of acquisition, and CD4 counts and viral parameters (including viral 
load, clade and genotype of the virus) at the time of diagnosis. 
6.4.2.2 The HIV liaison nurse has clinical responsibility for care of patients with HIV and 
will obtain information on identity and practice registration of new diagnoses from general 
practice and from Homerton Pathology. 
6.4.2.3 The HIV liaison nurse may ask GPs to obtain written informed consent from 
patients to allow divulgence of the above anonymised variables from their medical records. 
Copies of written informed consent will be retained by the HIV liaison nurse. 
6.4.2.4 For patients registering at Homerton Hospital, written informed consent may 
additionally be obtained by GCP-trained Homerton clinicians. 
6.4.2.5 For the few patients registering with GUM clinics other than Homerton, Dr Sarah 
Creighton, the NHS City & Hackney community liaison consultant, will arrange for written 
informed consent to be taken by herself or a GCP-trained member of her team with potential 
assistance from surgery GPs. 
6.5 Registration procedure and pre-test discussion 
6.5.1 All patients aged 16 years and above registering who are able to communicate in 
English or using a suitable translator will be offered a rapid HIV point of care test as part of 
the new patient health check. 
6.5.2 During the course of the new patient health check, the health care assistant or 
practice nurse will provide a short pre−test discussion and offer a rapid HIV test. 
6.6 Giving the test result and the post-test discussion 
6.6.1 A Non-Reactive rapid test result 
1. Following a non-reactive result, the patient will be assured that they do not have HIV. 
2. Any patient with recent risk will be advised to have a blood test from the arm one and 
three months after the most recent exposure. Recent risk will be defined as having had 
within the three previous months any of the following: medical procedures abroad including 
blood transfusions and tattoos; unprotected sex or sharing needles. 
6.6.2 Two consecutive Invalid reactive tests occurring during the same consultation 
1. Any patient with two consecutive invalid results and a NEGATIVE blood test without 
recent risk will be reassured they do not have HIV. 
2.  Any patient with two consecutive invalid results and a NEGATIVE blood test result but 
recent risk will be advised to have repeat serology one and three months after the most 
recent exposure. 
REC:09/H0722/67_RHIVA2_Trial_Protocol_v5.0_04May2012   Page 20 of 39 
 
                Confidential: this protocol may only be disseminated with the permission of the chief investigator 
3. Any patient with two consecutive invalid results and a NEGATIVE blood test but recent 
risk and symptoms suggestive of sero-conversion will be offered a repeat serology test 
within one and three month time following most recent exposure or referral to Homerton to 
exclude early HIV infection. 
6.6.3 An Indeterminate rapid test result 
1. If the confirmatory test is POSITIVE, the GP will refer the patient to the HIV Liaison 
Nurse and follow the confirmed HIV positive algorithm. 
2. If the confirmatory test is NEGATIVE, the GP uses clinical judgement to determine 
whether the patient is potentially sero-converting.  Any patient with recent risk should be 
offered repeat serology one and three months after most recent exposure. Alternatively, the 
GP may consider referring the patient to Homerton Hospital to exclude early HIV infection. 
 
The GP may wish to inform the HIV Liaison nurse about an indeterminate test prior to 
receiving the confirmatory test result. 
 
6.6.4 A Reactive rapid test AND a Positive confirmatory result (concordant result) 
A concordant result is one in which the result from the INSTI HIV1&2 Antibody kit is reactive 
and the subsequent Homerton/BLT Virology results are positive. 
 
If the confirmatory result is POSITIVE, Barts Virology will inform the GP and the HIV Liaison 
nurse via telephone. The HIV Liaison nurse will contact the GP to confirm the result. The GP 
will invite the patient to re-attend the surgery to learn about the test result. During this 
consultation, the GP will refer the patient to the HIV Liaison Nurse at Homerton Hospital. At 
Homerton Hospital, patients will be asked by GCP-trained clinicians for written informed 
consent for divulgence of anonymised data from their medical records. These anonymised 
data include CD4 count and viral load at the time of diagnosis; as well as mode of diagnosis, 
patient ethnicity, age, gender and Soundex code. If a confirmed HIV patient chooses to take 
up their specialist care at a GUM clinic other than the Homerton Department of Sexual 
Health, Dr Sarah Creighton from Homerton Hospital will chase up the required patient 
specific data for the study. For details on how GPs can obtain written informed consent, 
please see section 6.4.1. 
 
The GP may wish to inform the HIV Liaison nurse about a reactive test prior to receiving the 
confirmatory test result. 
6.6.5 A Reactive rapid test but a Negative confirmatory result (discrepant result) 
A discrepant result is one in which the result from the INSTI HIV-1/2 Rapid Antibody test is 
reactive and the subsequent laboratory result proves negative. 
 
6.6.5.1 The GP has responsibility for patients with discrepant results 
If the confirmatory result from Virology is negative, responsibility for patient care lies with the 
General Practitioner having been notified by Homerton Pathology. 
6.6.5.2 Patient follow-up at the GP surgery 
If the result is known prior to the patient’s follow up appointment, the General Practitioner 
should inform the patient at the earliest opportunity by telephone and the patient should be 
informed that it is likely that the INSTI HIV-1/2 Rapid Antibody test was a false reactive 
result. The patient should be invited to attend the surgery to talk about possible symptoms of 
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HIV sero-conversion, the use of barrier methods until their final HIV status is confirmed and 
to discuss the need for a referral to Homerton Hospital for exclusion of an early HIV 
infection. 
 
If the patient prefers to be retested at the surgery, the GP sends the second confirmatory 
blood test to Homerton Pathology. 
6.6.5.3 Patient follow-up at Homerton Hospital 
If the patient is referred to Homerton, a second confirmatory test and an EDTA sample for 
HIV pro-viral DNA test will be obtained. This will determine whether the patient is sero-
converting or truly negative. The HIV Liaison Nurse or a deputy should make a further 
appointment to see the patient in 10 working days to inform them of the result of the HIV 
antibody +/- the pro-viral DNA test/s. 
 
The HIV Liaison Nurse sends the second confirmatory blood test to Homerton Pathology. 
6.6.5.4 Quality control check 
The HIV Liaison Nurse informs the Practice HIV Lead Nurse and the RHIVA 2 team about 
any discrepant result. The RHIVA 2 team then arranges for a quality control check to be 
done as soon as possible, using the same batch number as the false reactive test and the 
internal quality control sera. Once this has been done, the RHIVA 2 team confirms the 
outcome by e-mail to the Practice GP, the Practice HIV Lead Nurse, and the BLT Virology 
POCT Lead. The outcome of this test is then recorded appropriately on the INSTI HIV1 & 2 
Antibody Internal Quality Control Result Sheet by the person performing the quality control 
check.  If a quality check has been done on the same day as the false reactive is received, 
the quality check need not be repeated. If a false reactive quality check is done, this can 
replace the regular quality control check if it is due. 
 
6.6.6 Repeat testing following risk exposure 
The British Association for Sexual Health and HIV (BASHH, 2010) gives the following advice 
on repeat testing following risk exposure: Patients attending for HIV testing who identify a 
specific risk occurring more that 4 weeks previously, should not be made to wait 3 months 
(12 weeks) before HIV testing. They should be offered a 4th generation laboratory HIV test 
(available at Homerton Hospital) and advised that a negative result at 4 weeks post 
exposure is very reassuring/highly likely to exclude HIV infection. An additional HIV test 
should be offered to all persons at 3 months (12 weeks) to definitively exclude HIV infection. 
Patients at lower risk may opt to wait until 3 months to avoid the need for HIV testing twice. 
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Flow diagram for RHIVA intervention GP surgeries 
Registration: 
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and GCP-trained Homerton clinician obtains written 
informed consent
Homerton HIV Research Nurse informs research team 
using anonymised data
Reactive, 
Indeterminate 
or 2x Invalid
Decline NPHC Non-ReactiveDecline test
 
6.7 Follow-up procedures 
Any patient with a reactive, indeterminate or 2x invalid HIV rapid test will be seen by the GP 
immediately for information; a further test and specialist follow up if indicated (see Flow 
diagram for RHIVA intervention GP surgeries). The HIV liaison nurse, a member of the 
clinical management team at the Department of Sexual Health at Homerton Hospital, will 
liaise with both GP surgeries and Homerton Pathology at least fortnightly to minimise the 
loss of patients followed up in specialist care. If a patient fails to attend specialist follow up, 
the HIV research nurse will make appropriate attempts to contact the patient. 
6.8 Laboratory assessments 
6.8.1 Rapid HIV test 
The rapid HIV test will be performed using the INSTI HIV-1/HIV-2 Rapid Antibody Test 
(bioLytical Laboratories, Canada) according to the manufacturer’s instructions. The INSTI 
test device has CE-marking and detects antibodies to the Human Immunodeficiency Virus 
Type 1 and Type 2. Briefly, 50 microlitres of blood drawn from a finger prick using a pipette 
is mixed with a Sample Diluent and poured onto a Sample Membrane. Signals are visualised 
by applying a Colour Developer onto the membrane and by de-staining the background 
using a Clarifying Solution. Results are available in 60 seconds. A single dot (control) on the 
Sample Membrane indicates a negative result; an additional blue test dot suggests HIV 
infection, and any other staining pattern including the absence of any signal indicates an 
invalid result. For further information, please see 
http://www.biolytical.com/ourtechnology.html. 
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6.8.2 CD4 counts and viral parameters including  HIV viral load, clade and 
genotype of the virus 
Laboratory assessments of immunological and viral endpoints specified in section 8.1.2.1 of 
this protocol will be performed according to approved standard operating procedures. 
6.9 Withdrawal 
6.9.1 Withdrawal of subjects 
Subjects will be withdrawn from the study if they withdraw consent to participate. 
 
6.9.1.1 When and how to withdraw subjects 
Subjects will not be asked to specify reasons for withdrawal from the study. Patients who 
have given consent, but lose capacity to consent during the study will be withdrawn from the 
study. However, identifiable data or blood already collected would be retained and used in 
the study. No further data would be collected in relation to the patient. 
 
6.9.1.2 Data collection and follow-up for withdrawn subjects 
The HIV research nurse will make appropriate attempts to contact any withdrawn HIV 
positive subject who fails to attend HIV specialist follow up. Only non-identifiable patient 
information collected with consent will be used and retained in the study. 
 
6.9.2 Withdrawal of surgeries 
Surgeries will be withdrawn from the study if they withdraw consent to participate. A note of 
the conversation with the practice manager or the lead GP stating the date and reason for 
withdrawal needs to be made and signed by the CI for filing in the Trial Master File. Any 
unused INSTI test kits left at the surgery and the GP folder including the records from the 
Quality Assurance program need to be removed from the surgery premises once the RHIVA 
2 team has been notified about the study withdrawal by the surgery. 
6.9.2 Data Handling and Record Data collection and follow-up for withdrawn 
subjects 
The HIV research nurse will make appropriate attempts to contact any withdrawn HIV 
positive subject who fails to attend HIV specialist follow up. Only non-identifiable patient 
information collected with consent will be used and retained in the study. 
7 Data Handling and Record Keeping 
7.1 Confidentiality 
Subjects’ personal data will remain confidential, and will be handled, processed, stored and 
destroyed according to the terms of the Data Protection Act 1998. 
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7.2 Study documents 
Study documentation will be maintained in a Trial Master File, to be stored at the Centre for 
Health Sciences, Barts and The London Medical School. 
7.3 Case report forms 
Case Report Forms will include the following data: anonymised patient study identifier, 
participants’ demographic details (including age, gender, ethnicity and Soundex code), 
checklist of eligibility criteria, mode of diagnosis; and results from CD4 counts and viral 
parameters such as viral load, clade and genotype of the virus. 
7.4 Record retention and archiving 
Trial records will be retained for 20 years. Records will be stored in the Centre for Health 
Sciences, Barts and The London Medical School while the study is being conducted, after 
which they will be transferred to the QMUL archive. 
7.5 Compliance 
The CI and the Principal Investigator will ensure that this study is conducted in accordance 
with the latest version of the “Declaration of Helsinki” (http://www.wma.net/e/policy/b3.htm). 
The study will adhere to the principles outlined in the Guidelines for Good Clinical Practice. 
7.6 Definition of the end of the study 
The end of the study will be defined as the date when the patient recruitment phase has 
been completed defined as sufficient patient accrual to meet the study power requirements 
[expected to be 24 months] (see section 8.2.1) and the HIV research nurse has checked that 
all HIV positive patients have been referred to specialist care. 
8 Clinical Governance Issues 
8.1 Ethical considerations 
The main ethical considerations arising from the design and conduct of this trial are as 
follows: 
8.1.1 Rationale for research 
We have thoroughly reviewed existing literature and consulted with a wide range of 
professional and non-professional stakeholders for the planning and design of this study. 
HIV continues to spread in the UK despite enormous public efforts to curb the epidemic. 
REC:09/H0722/67_RHIVA2_Trial_Protocol_v5.0_04May2012   Page 25 of 39 
 
                Confidential: this protocol may only be disseminated with the permission of the chief investigator 
Current specialist consensus states that HIV testing should be expanded into Primary Care, 
particularly in areas such as Hackney where the disease is highly endemic.  
8.1.2 Design of research 
Ethical research must employ the most appropriate design in order to answer the research 
question. When investigating effectiveness of a clinical intervention at the GP practice level, 
a cluster randomised, controlled trial is the gold standard methodology. 
8.1.3 Minimisation of inconvenience, discomfort and risk for participants 
During the pre−test discussion, patients may feel uncomfortable talking about past risk 
exposures and their sex life. They may also find it inappropriate to discuss issues like these 
in a Primary Care setting. 
Patients may feel anxious about HIV testing, but we have shown that most patients 
welcomed rapid HIV testing if offered as part of the routine GP registration process (Prost et 
al., 2009). 
Patients will be informed that they may experience minor pain during the finger prick HIV 
test. The rapid HIV test will be carried out at the beginning of a consultation and results will 
be available immediately to alleviate anxiety. 
Patients with 2 consecutive invalid rapid test results will learn that the test cannot be 
interpreted and that they are not more likely to have HIV. This group of patients will be 
offered by their GP a standard HIV test from venous blood to confirm their HIV status. 
Patients with a reactive rapid HIV test will be seen by their GP immediately for further 
information, a confirmatory HIV test and specialist referral. 
Most patients with an HIV diagnosis will feel emotionally distressed and make changes to 
their lifestyles. However, all patients will be given sufficient time to consider whether they 
wish to participate in the study and at no time they will be pressurised to undergo an HIV 
test. They will also be made aware that neither refusal to participate nor a HIV diagnosis will 
have an effect on the quality of care they receive from their health care provider. All health 
care professionals including GPs, nurses and health care assistants involved in patient care 
will be instructed in providing support for patients with a positive diagnosis. 
Finally, patients will be made aware of the fact that having an HIV test will not itself affect 
future life insurance applications, but that an HIV infection would have to be declared on 
such applications. 
8.1.4 Recruitment procedure 
The study is designed in a way that allows for broad patient recruitment. Firstly, anyone 
aged 16 years and older registering with a GP will be invited to participate. Secondly, patient 
information sheets will be translated into the most commonly locally spoken non-English 
languages including French, Turkish and Vietnamese. Finally, patients who are unable to 
undertake the pre-test discussion in English will be invited to use a suitable interpreter.  
8.1.5 Confidentiality 
We will ensure that participants' personal data remain confidential. Our procedures for 
handling, processing, storage and destruction of data are compliant with the Data Protection 
Act 1998. 
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8.1.6 Data handling and record keeping 
Case report forms will be anonymised and held in locked filing cabinets in the Centre for 
Health Sciences, Barts and The London School of Medicine and Dentistry. Only trial staff will 
have access to these. Trial staff will enter all non-identifiable patient data from case report 
forms into an electronic database held on a password protected internal hard drive on stand-
alone computer, linked to an ID code, which will be unique for each trial participant. A back-
up copy will be held on a password-protected file on the internal hard drive of a stand-alone 
desk-top computer by Sandy Smith, data manager. Both stand-alone computers will be kept 
in a locked office in the Centre for Health Sciences, Barts and The London School of 
Medicine and Dentistry. Only practice GP staff and the HIV liaison nurse will have access to 
identifiable patient data. The other members of the research team will not have access to 
patient identifiable information. Representatives of the sponsor, participating NHS Trusts or 
regulatory authorities will be the only people with potential access to view study data that 
could be linked to identifiable patient information. 
8.2 Audit and inspection 
Trial documentation will be made available to auditors and inspectors representing the 
sponsor and the regulatory authorities. Representatives of the Pragmatic Clinical Trials Unit 
at QMUL will perform regular audits on document filing, standard operating procedures and 
consenting on the RHIVA 2 trial. 
8.3 Reporting of serious breaches in GCP or trial protocol 
Serious breaches in Good Clinical Practice (GCP) and serious breaches of the trial protocol 
will be reported to the sponsor. 
8.4 Quality assurance 
Data quality will be audited according to GCP guidelines, and a trail will be maintained of any 
change or correction to the case report form or the electronic database. The sponsor will 
have direct access to all trial-related sites, source data and reports in order to ensure that 
the trial is conducted, and data are generated, recorded and reported in compliance with the 
protocol and with GCP. 
In addition, quality assurance we will be achieved by 1) using a rapid HIV test device (INSTI 
HIV1&2 Rapid Antibody Kit, bioLytical Laboratories, Canada) that has CE-marking and has 
been shown to be highly accurate and 2) by setting up a quality assurance scheme with the 
Department of Virology at Barts and The London NHS trust. 
8.5 Data monitoring committee 
A data monitoring committee (DMC) will be established for the trial. The chair of the DMC 
will keep a record of DMC communications and activities. The central responsibilities of this 
DMC will be to make recommendations to the sponsor and the Trial Steering Committee on 
further conduct of this trial, based on results of the monitoring procedures described below. 
Such recommendations could include continuing or terminating the trial, or modifying its 
protocol. Any such modifications should not violate the concepts behind the original study 
protocol. If changes in the study conduct are recommended by the DMC, sufficient 
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information should be provided to allow the sponsor and the CI to decide whether and how 
to implement them. The implementation of any DMC recommendation is the responsibility of 
the sponsor and CI who are also free to neglect (in whole or in part) any recommendations 
of this DMC. The sponsor and the investigators bear the final responsibility for the conduct of 
the trial. This responsibility cannot be transferred to the DMC. 
8.5.1 Monitoring procedures 
Six months following the start date of the trial, the trial statistician will perform an interim 
analysis using the statistical methods specified in the protocol to analyse study outcome 
measures and provide the DMC with data and analysis for checking. The DMC will review 
accumulating data in an un-blinded fashion in order to monitor the study conduct. The 
accumulating data will be available to the DMC as well as to the study statistician and the CI. 
Interim data and analyses by trial arm (and the deliberations of the DMC) should be 
available only to those present in the closed session i.e. only members of the DMC as 
agreed by the DMC. However, the DMC can decide whether to invite the study statistician 
and/or the CI to take part in the closed session. However, the DMC may in the closed 
session share confidential information with the study statistician if they consider it necessary 
(see Section 7, DMC charter). In view of the low recruitment at the beginning of the trial and 
a change in the primary outcome measure, the study statistician will perform an additional 
interim analysis 18 months after the start date of the trial. If a significant difference between 
intervention and control groups for the primary outcome is detected at interim analysis (P-
value <0.001), the DMC may recommend that the trial be stopped early. 
8.5.2 Declaration of possible conflicts of interest of DMC members 
The members of the DMC have no involvements that might raise the question of bias in their 
reports to the sponsor or investigators in this study. Specifically, they have no financial 
interest in the outcome of this study, and they will not be authors on publications arising from 
this study.   
8.5.3 Frequency and format of DMC meetings 
It is anticipated that the DMC will meet up once before the start or during the early stages of 
the trial; and that any future communication can be conducted by email and telephone call, 
rendering any additional physical meeting between members, investigators and 
representatives of the sponsor unnecessary. The DMC will check the effectiveness analysis 
six months after beginning of the study.  
8.5.4 Communication procedures 
The DMC will communicate results of the assessment of the effectiveness analysis by email 
to the Trial Steering Committee. 
8.5.5 Responsibilities, timelines and methodological aspects 
Members of the DMC will be jointly responsible for checking the interim effectiveness 
analysis. It is anticipated that the results of these checks will be available to the Trial 
Steering Committee within three weeks of submitting data to the DMC. 
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8.5.6 Documentation of the DMC activities 
The DMC will not share the results of the assessment of the interim effectiveness analysis 
with the CI unless the decision has been made to stop the trial. Any safety issues, 
recommendations to amend the protocol and suggestions with regard to patient recruitment 
arising in the interim analysis however will be shared with the CI. 
9 Trial Steering Committee 
The TSC will monitor and supervise the progress of the trial towards its interim and overall 
objectives. The TSC will also review at regular intervals relevant information from other 
sources and consider recommendations to the Data Monitoring Committee. The TSC 
members will nominate a chairmen and meet at the beginning of the trial and then annually. 
The CI will organise the TSC meetings, which may be attended by representatives of the 
investigators. The TSC will also be invited to read and comment on any draft publications 
that report outcome measures and/ or details of the DMC. 
10 Statistics 
10.1 Endpoints 
10.1.1 Primary endpoint 
The primary outcome measure for this trial is: 
Mean CD4 count of newly diagnosed HIV patients in general practice after square root 
transformation. Using the Normal distribution, the percentage of patients who present with 
advanced HIV infection as measured by CD4 count <200 cells per cubic millimetre of blood 
will be estimated. A newly diagnosed HIV patient in general practice is defined as a person, 
who is unaware of their HIV status at the time of testing but who tests either HIV 1 or HIV 2 
antibody positive following a GP request for HIV confirmatory testing at Homerton Pathology. 
All patients including antenatal patients whose tests are requested from general practice will 
be included. Patients of unknown HIV status in whom the GP has not performed HIV testing 
prior to referral and who are referred by their GP to secondary care at Homerton Hospital 
either for HIV testing or for further management of a suspected HIV-related illness are 
excluded from the primary outcome measure. 
10.1.2 Secondary endpoints 
10.1.2.1 Clinical outcomes 
 Numbers of newly diagnosed patients in general practice 
 Proportion of newly diagnosed patients in general practice 
 Percentage of patients that qualify for the initiation of anti-retroviral treatment, defined as 
CD4 count lower than 350 cells per microlitre of blood, as estimated from mean CD4 
count. 
10.1.2.2  Viral outcomes 
 Numbers of HIV cases with a high risk of progression to AIDS, defined as a viral load of 
higher than 200,000 HIV-1 RNA copies per million peripheral mononuclear cells as a 
predictor of disease progression 
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 Clade and genotype of the virus at the time of diagnosis as predictors of disease 
progression 
10.1.2.3  Health service use 
 Numbers of standard HIV tests done opportunistically 
 Numbers of rapid HIV tests done in new patient health checks and at first patient 
consultations. 
10.1.2.4  Economic outcomes 
 Cost−effectiveness of the intervention compared to standard of care. 
10.1.3 Study definitions 
Early HIV disease in a subject will be defined as that subject having a CD4 count of 200 or 
more cells per cubic millimetre at the time of diagnosis. 
10.2 Statistical considerations 
10.2.1 Sample size 
The analysis will compare mean CD4 count in the intervention and control groups. To aid 
interpretation this will be converted into the estimated numbers less than 200 and less than 
350 using the normal distribution, based on the square root of the CD4 count. 
 
Data were obtained from the Department of Sexual Health at Homerton Hospital for the 
period 1st April 2009 to 31st March 2010.  The mean CD4 count in 18 cases was 300 
cells/ml (SD = 200). On the transformed scale, the mean was 17 and the SD 6.  The intra-
cluster correlation coefficient (ICC) is assumed to be 0.05, a value typical in GP settings.  
We assume that 20 practices will be randomised to screening and 20 to control. We also 
assume that screening practices will identify twice as many cases as control practices. 
Allowance is also made, following the method of Eldridge and Kerry (2006) for practices to 
recruit variable numbers of patients and allowing for some practices to fail identifying any 
cases (Kerry and Martin Bland, 2001; Eldridge et al., 2006). Power is 80% at the 5% 
significance level. 
Allowing for clustering, we would need to identify 48 new cases in screening practices and 
23 in control practices in order to be able to detect an increase in the mean CD4 count from 
306 to 470, which corresponds to a reduction in the proportion of late presenters from 30% 
to 10%.  This should be feasible if the trial continues until May 2012. 
10.2.2 Cluster randomisation 
Practice will be randomised using a computer generated minimisation, by: 1) practice list 
size {≤ 5000; > 5000 - < 7000;  7000} 2) practice deprivation {IMD Score < 47;  47} and 3) 
HIV male testing rate per surgery {< 7;  7}. 
10.2.3 Planned patient recruitment rate 
All patients aged 16 years and older registering with a GP surgery during the study period 
will be invited to participate. 
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10.3 Statistical analysis 
Statistical analysis will be performed with the assistance of a suitably qualified statistician. 
10.4 Frequency of analysis 
An effectiveness analyses will be conducted 6 months after the start of the recruitment 
period and on termination of the trial. A plan of statistical analysis will be drawn up and 
agreed with TSC prior to closure of the dataset. In view of the low recruitment at the 
beginning of the trial and the change in the primary outcome measure, an additional interim 
analysis will be conducted 18 months after the start date of the trial. 
10.5 Analysis of participants’ baseline characteristics 
Following data entry and data cleaning, baseline characteristics including age, sex, ethnic 
group and Soundex code and viral parameters including HIV viral load, clade and genotype 
of the virus will be descriptively compared between intervention and control groups. 
10.6 Analysis of study endpoints 
The CD4 count of all patients registered with the practice in the period from randomisation of 
the practice to the end of the trial will be compared in the intervention and control groups 
using regression analysis to adjust for stratification factors and clustering. Data will be 
transformed using a square root transformation prior to analysis. Difference in mean CD4 
count and 95% confidence interval will be presented. Proportions of patients less than 200 
and less than 350 in each group will be estimated using the normal distribution. A secondary 
analysis will also adjust for CD4 count per practice in the period from 12 months prior to 
study start to randomisation of the practice, if there are sufficient cases diagnosed.  
The primary analysis will be by intention to treat. A secondary per protocol analysis will be 
carried out, comprising practices that initiated regular screening for HIV and excluding those 
that did not. 
 
10.7 Health economic analysis 
The costs adding HIV screening onto routine health checks within GP practices in Hackney 
will be estimated using established costing methods (Kumaranayake et al., 2000; Drummond 
et al., 2005). The incremental financial and economic costs will be collected from the 
provider’s perspective for the one year of the intervention. The financial costs represent the 
actual expenditures on goods and services used in the intervention. Economic costs 
represent the value of all resources used. This includes the costs of donated goods and 
services. The provider is considered the PCT. Start-up costs, including training, will be 
collected and treated as a capital cost. Cost data will be collated from project accounts, 
observations of intervention implementation (not during post-test discussion), interviews with 
medical staff implementing HIV testing in both intervention and control clinics and a self-
complete time allocation questionnaire for these medical staff. Total costs per clinic in each 
arm of the intervention will be estimated as will the cost per person tested, cost per positive 
case identified, cost per early case detected. 
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10.8 Interim analysis 
An effectiveness analysis will be conducted six months after the beginning of the recruitment 
phase. In view of the low the initial low recruitment and the change in the primary outcome 
measure, an additional effectiveness analysis will be conducted 18 months after the 
beginning after the start date of the trial. This will be undertaken blind to allocation of 
practices and will include the following outcomes; CD4 count, percentage of HIV positive 
patients diagnosed in primary care, number of standard HIV tests performed 
opportunistically. 
11 Study Finances 
11.1 Funding source 
This Trial is funded by the NHS City and Hackney, the Department of Health and Central 
and East London Local Research Network (CLRN). 
11.2 Subject expenses and payments 
Subjects will not receive any payments for participating in the study. 
12 Sponsorship and Indemnity 
Queen Mary, University of London will sponsor this trial. The Joint Research Office for 
Queen Mary, University of London will arrange for suitable indemnity for negligent harm 
arising as a result of participation in this study to be in place. 
13 Publication Policy 
Any manuscript reporting trial findings will be prepared according to CONSORT guidelines 
and submitted to peer-reviewed biomedical journals according to ICMJE Uniform 
Requirements. Authorship will be based on individuals’ contribution to study design, conduct, 
analysis, drafting/revision of manuscript and final approval of the version to be published. 
Authorship will not necessarily be restricted to individuals named on this protocol; neither is 
authorship guaranteed to any individual named on this protocol. Contributors who do not 
meet authorship criteria will be listed in ‘Acknowledgements’. 
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15 Attachments 
Attachment 1: 
 
NHS City and Hackney Teaching Primary Care Trust 
Information about a Research Project: 
Can rapid HIV testing improve the diagnosis of HIV infection in general practice? 
Part 1: 
Your practice is taking part in a research study and we would like to invite you to take part. 
Before you decide we would like you to understand why the research is being done and what 
it would involve for you.  
 
 What is the purpose of the study? 
The study compares shorter and slightly longer health checks. The longer health check 
includes a brief discussion about HIV and an offer of a HIV test that gives an immediate result. 
We want to find out whether surgeries offering this rapid test detect more people with the 
infection. 
 
 Why have I been invited? 
All those aged 16 years and older joining a GP practice are invited to take part.  
 
 Do I have to take part? 
It is up to you to decide whether to join the study. You are free to withdraw at any time, 
without giving a reason. This would not affect the standard of care you receive. 
 
 What is involved in taking part? 
When you join the surgery you may be offered a health check. Which check your practice 
offers has been decided by chance. Your practice is offering the slightly longer one that 
includes a brief discussion about HIV and an offer of the rapid test. This involves taking 
a small amount of blood from a finger prick. You will get your result immediately. 
 
The possible test results are: non-reactive, reactive, and invalid. What do these mean? 
1. Non-reactive: Most people will have a non-reactive test result and will be reassured they 
do not have HIV. If you have had a non-reactive test and have had unprotected sex or have 
shared needles within the previous three months, you will be advised to repeat the HIV test 
in three months time to ensure that you have not acquired the infection in that so-called 
‘window’ period. 2. Reactive: A small minority of people will have this test result and if you 
do, you will be seen by your GP and given more information.  You will have another blood 
sample taken (approximately one teaspoonful) taken from a vein in the arm near the elbow 
joint so that the test can be repeated in a laboratory. You will be given full support and time 
with a GP to discuss what this means, and you will be given an appointment with a specialist. 
If the laboratory test confirms that you have HIV infection, your GP will ask you to agree (in 
writing) to give access to selected aspects of your medical records to record research data. 
3. Invalid: This means that the test result cannot be interpreted and it does not suggest that 
you have HIV. A GP will see you immediately to offer you more information and a standard 
HIV test from venous blood. 
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 What will I have to do? 
We only ask you to read this information sheet before attending the new patient health 
check, and to decide whether you wish to have a test. 
 
 What are the alternatives for diagnosis? 
The standard HIV test using venous blood taken from a vein in your arm is also available at 
the surgery. The result of this test will be available within one week. 
 
 Are there any disadvantages, risks or dangers for me if I take part? 
There may be minor discomfort due to the finger prick test. Having an HIV test will not itself 
affect future life insurance applications. However, HIV infection would have to be declared on 
such applications. 
 
 Are there any benefits for me if I take part? 
Yes. You will know whether or not you have HIV. The few diagnosed with the infection will 
receive full support and learn how to protect partners and children. 
 
 What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
 Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
total confidence. The details are included in Part 2. 
Part 2: 
 What if new relevant new information becomes available? 
If the study is stopped early for any reason, we will tell you and give appropriate advice. 
 
 What will happen if I don’t want to carry on with the study? 
We will need to use data collected up to your withdrawal. Patients needing a blood test 
because of a rapid, or invalid HIV test, can ask for any stored blood samples that can still be 
identified as theirs to be destroyed if they wish. 
 
 What would happen if, once given informed consent, I lose capacity to consent 
during the study? 
You would be withdrawn from the study. Identifiable data or blood already collected would be 
retained and used in the study. No further data would be collected in relation to you. 
 
 What happens if there is a problem? 
We would not expect you to suffer any harm or injury because of your participation in 
this study. If you are harmed by taking part in this study, there is no special compensation 
arrangement. If you are harmed due to someone’s negligence, then you may have grounds 
for legal action, but you may have to pay your legal costs. Regardless of this, if you wish to 
complain or have any concerns about any aspect of the way you have been approached or 
treated during the course of this study, the normal NHS complaints mechanisms should be 
available to you. 
 
Please contact Patient Advisory Liaison Service (PALS) if you have any concerns regarding 
the care you have received, or as an initial point of contact if you have a complaint.  Please 
telephone 020 7377 6335, minicom 020 7943 1350, or email 
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pals@bartsandthelondon.nhs.uk, you can also visit PALS by asking at any hospital 
reception. 
 
If you want to find out more about this study, please leave a message on our dedicated 
phone line (Telephone: 0207 882 7084) saying what language you speak and when is a 
good time for you to talk. The research team will then arrange for a fluent speaker to call you. 
 
 Will my taking part in this research be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the surgery will have your 
name and address removed so that you cannot be recognised (if it is applicable to your 
research). 
 
 What will happen to any samples I give? 
Finger prick blood applied onto the rapid HIV test device will be disposed of immediately. 
Venous blood taken from the few patients with a reactive, or invalid rapid test will be sent to 
established clinical laboratories and disposed of according to standard laboratory 
procedures. 
 
 Will any genetic tests be done on humans? 
No. 
 
 What will happen to the results of the study? 
Results of the study will be published in scientific journals and presented at conferences. 
Patients will be informed about the results by a leaflet distributed in GP surgeries. 
 
 Who is organising and funding the research? 
The study is organised by Barts and The London School of Medicine and Dentistry and 
funded by the City and Hackney Teaching Primary Care Trust. 
Attachment 2 
 
NHS CITY AND HACKNEY TEACHING PRIMARY CARE TRUST 
Information about a Research Project: 
Can rapid HIV testing improve the diagnosis of HIV infection in general practice? 
Part 1: 
Your practice is taking part in a research study and we would like to invite you to take part 
too. Before you decide we would like you to understand why the research is being done and 
what it would involve for you.  
 
 What is the purpose of the study? 
The study compares shorter and slightly longer health checks. The longer health check 
includes a brief discussion about HIV and an offer of a HIV test that gives an immediate 
result. We want to find out whether surgeries offering this rapid test detect more people with 
the infection. 
 
 Why have I been invited? 
All those aged 16 years and older joining a GP practice are invited to take part.  
REC:09/H0722/67_RHIVA2_Trial_Protocol_v5.0_04May2012   Page 36 of 39 
 
                Confidential: this protocol may only be disseminated with the permission of the chief investigator 
 
 Do I have to take part? 
It is up to you to decide whether to join the study. You are free to withdraw at any time, 
without giving a reason. This would not affect the standard of care you receive. 
 
 What is involved in taking part? 
When you join the surgery you may be offered a health check. Which check your practice 
offers has been decided by chance. Your practice is providing the shorter, standard 
check that will not include the offer of a rapid HIV test.  
 
 What will I have to do? 
We only ask you to read the information sheet before attending the new patient health 
check, and to decide whether you wish to take part. 
 
 What are the alternatives for diagnosis? 
The standard HIV test using venous blood taken from a vein in your arm is available at the 
surgery. The result of this test is available within one week. 
 
 Are there any disadvantages, risks or dangers for me if I take part? 
No. 
 
 Are there any benefits for me if I take part? 
Yes, you will be offered a routine health check. 
 
 What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
 Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
Part 2: 
 What if new relevant new information becomes available? 
If the study is stopped early for any reason, we will tell you and give appropriate advice. 
 
 What will happen if I don’t want to carry on with the study? 
We will need to use data collected up to your withdrawal. Patients needing a blood test as 
part of the study can ask for any stored blood samples that can still be identified as theirs to 
be destroyed if they wish. 
 
 What would happen if, once given informed consent, I lose capacity to consent 
during the study? 
You would be withdrawn from the study. Identifiable data or blood already collected would be 
retained and used in the study. No further data would be collected in relation to you. 
 
 What happens if there is a problem? 
We would not expect you to suffer any harm or injury because of your participation in 
this study. If you are harmed by taking part in this study, there is no special compensation 
arrangement. If you are harmed due to someone’s negligence, then you may have grounds 
for legal action, but you may have to pay your legal costs. Regardless of this, if you wish to 
complain or have any concerns about any aspect of the way you have been approached or 
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treated during the course of this study, the normal National Health Service complaints 
mechanisms should be available to you. 
 
Please contact Patient Advisory Liaison Service (PALS) if you have any concerns regarding 
the care you have received, or as an initial point of contact if you have a complaint.  Please 
telephone 020 7377 6335, minicom 020 7943 1350, or email 
pals@bartsandthelondon.nhs.uk, you can also visit PALS by asking at any hospital 
reception. 
 
If you want to find out more about this study, please leave a message on our dedicated 
phone line (Telephone: 0207 882 7084) saying what language you speak and when is a 
good time for you to talk. The research team will then arrange for a fluent speaker to call 
you. 
 
 Will my taking part in this research be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the surgery will have your 
name and address removed so that you cannot be recognised (if it is applicable to your 
research). 
 
 What will happen to any samples I give? 
Venous blood taken as part of the study will be sent to established clinical laboratories and 
disposed of according to standard laboratory procedures. 
 
 Will any genetic tests be done on humans? 
No. 
 
 What will happen to the results of the research study? 
Results of the study will be published in scientific journals and presented at conferences. 
Patients will be informed about the results by a leaflet in GP surgeries. 
 
 Who is organising and funding the research? 
The study is organised by Barts and The London School of Medicine and Dentistry and 
funded by the City and Hackney Teaching Primary Care Trust. 
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Table 1: CONSORT 2010 checklist of information to include when reporting a cluster 
randomised trial  
Section/Topic+ Item+
No+
Standard+Checklist+item+ Extension+for+cluster+
designs+
Page+
No+*+
Title+and+abstract+ !
+ 1a! Identification!as!a!
randomised!trial!in!the!title!
Identification!as!a!cluster!
randomised!trial!in!the!title!
Page+1+
1b! Structured!summary!of!trial!
design,!methods,!results,!and!
conclusions!(for!specific!
guidance!see!CONSORT!for!
abstracts)1,2!
See!table!2! Page+2+
Introduction+ +
Background+and+
objectives+
2a! Scientific!background!and!
explanation!of!rationale!
Rationale!for!using!a!cluster!
design!
Page+3+
2b! Specific!objectives!or!
hypotheses!
Whether!objectives!pertain!to!the!
cluster!level,!the!individual!
participant!level!or!both!
Page+3+
Methods+ +
Trial+design+ 3a! Description!of!trial!design!
(such!as!parallel,!factorial)!
including!allocation!ratio!
Definition!of!cluster!and!
description!of!how!the!design!
features!apply!to!the!clusters!
Page 3 
3b! Important!changes!to!
methods!after!trial!
commencement!(such!as!
eligibility!criteria),!with!
reasons!
+ Page+6+
Participants+ 4a! Eligibility!criteria!for!
participants!
Eligibility!criteria!for!clusters!! Page+3+
4b! Settings!and!locations!where!
the!data!were!collected!
+ Pages+5,+6+
Interventions+ 5! The!interventions!for!each!
group!with!sufficient!details!
to!allow!replication,!
including!how!and!when!they!
were!actually!administered!
Whether!interventions!pertain!to!
the!cluster!level,!the!individual!
participant!level!or!both!
Page+3,+4+
Outcomes+ 6a! Completely!defined!preM
specified!primary!and!
secondary!outcome!
measures,!including!how!and!
Whether!outcome!measures!
pertain!to!the!!cluster!level,!the!
individual!participant!level!or!both!
Page+6+
CONSORT Cluster RCT checklist
Click here to download Necessary additional data: RHIVA2_Cluster RCT checklist.pdf
when!they!were!assessed!
6b! Any!changes!to!trial!
outcomes!after!the!trial!
commenced,!with!reasons!
+ Page+6+
Sample+size+ 7a! How!sample!size!was!
determined!
Method!of!calculation,!number!of!
clusters(s)!(and!whether!equal!or!
unequal!cluster!sizes!are!
assumed),!cluster!size,!a!
coefficient!of!intracluster!
correlation!(ICC!or!k),!and!an!
indication!of!its!uncertainty!
Page+7+
7b! When!applicable,!
explanation!of!any!interim!
analyses!and!stopping!
guidelines!
+ Page+6,+but+
results+of+
interim+analysis+
not+specified+
Randomisation:+ +
+Sequence+
generation+
8a! Method!used!to!generate!the!
random!allocation!sequence!
+ Page+4+
8b! Type!of!randomisation;!
details!of!any!restriction!
(such!as!blocking!and!block!
size)!
Details!of!stratification!or!
matching!if!used!
Page+4+
+Allocation+
concealment+
mechanism+
9! Mechanism!used!to!
implement!the!random!
allocation!sequence!(such!as!
sequentially!numbered!
containers),!describing!any!
steps!taken!to!conceal!the!
sequence!until!interventions!
were!assigned!
Specification!that!allocation!was!
based!on!clusters!rather!than!
individuals!and!whether!allocation!
concealment!(if!any)!was!at!the!
cluster!level,!the!individual!
participant!level!or!both!
Page+4+
+Implementation+
+
10! Who!generated!the!random!
allocation!sequence,!who!
enrolled!participants,!and!
who!assigned!participants!to!
interventions!
Replace!by!10a,!10b!and!10c! +
+ 10a! ! Who!generated!the!random!
allocation!sequence,!who!enrolled!
clusters,!and!who!assigned!
clusters!to!interventions!
!
Pages+3,+4++
+ 10b! ! Mechanism!by!which!individual!
participants!were!included!in!
clusters!for!the!purposes!of!the!
trial!(such!as!complete!
Page+4+
enumeration,!random!sampling)!
+ 10c! ! From! whom! consent! was! sought!
(representatives!of! the! cluster,!or!
individual! cluster! members,! or!
both),! and! whether! consent! was!
sought! before! or! after!
randomisation!
!
Page+4+
+ ! ! + +
Blinding+ 11a! If!done,!who!was!blinded!
after!assignment!to!
interventions!(for!example,!
participants,!care!providers,!
those!assessing!outcomes)!
and!how!
+ Pages+6,+10+
11b! If!relevant,!description!of!the!
similarity!of!interventions!
+ NA+
Statistical+methods+ 12a! Statistical!methods!used!to!
compare!groups!for!primary!
and!secondary!outcomes!
How!clustering!was!taken!into!
account!
Page+7+
12b! Methods!for!additional!
analyses,!such!as!subgroup!
analyses!and!adjusted!
analyses!
+ Page+7+
Results+ +
Participant+flow+(a+
diagram+is+strongly+
recommended)+
13a! For!each!group,!the!numbers!
of!participants!who!were!
randomly!assigned,!received!
intended!treatment,!and!
were!analysed!for!the!
primary!outcome!
For!each!group,!the!numbers!of!
clusters!that!were!randomly!
assigned,!received!intended!
treatment,!and!were!analysed!for!
the!primary!outcome!
Please+see++
Figure+1+
13b! For!each!group,!losses!and!
exclusions!after!
randomisation,!together!with!
reasons!
For!each!group,!losses!and!
exclusions!for!both!clusters!and!
individual!cluster!members!
Please+see+
Figure+1.+For+
loss+or+
practices,+see+
pages+7+and+8+
Recruitment+ 14a! Dates!defining!the!periods!of!
recruitment!and!followMup!
+ Page+8+
14b! Why!the!trial!ended!or!was!
stopped!
+ Page+8+
Baseline+data+ 15! A!table!showing!baseline!
demographic!and!clinical!
characteristics!for!each!
group!
Baseline!characteristics!for!the!
individual!and!cluster!levels!as!
applicable!for!each!group!
Tables+1a+and+
1b+
Numbers+analysed+ 16! For!each!group,!number!of!
participants!(denominator)!
included!in!each!analysis!and!
whether!the!analysis!was!by!
original!assigned!groups!
For!each!group,!number!of!
clusters!included!in!each!analysis!
Page+7+
Outcomes+and+
estimation+
17a! For!each!primary!and!
secondary!outcome,!results!
for!each!group,!and!the!
estimated!effect!size!and!its!
precision!(such!as!95%!
confidence!interval)!
Results!at!the!individual!or!cluster!
level!as!applicable!and!a!
coefficient!of!intracluster!
correlation!(ICC!or!k)!for!each!
primary!outcome!
Pages+8+and+9.+
For+ICC,+see+
page+7.+
17b! For!binary!outcomes,!
presentation!of!both!
absolute!and!relative!effect!
sizes!is!recommended!
+ +NA+
Ancillary+analyses+ 18! Results!of!any!other!analyses!
performed,!including!
subgroup!analyses!and!
adjusted!analyses,!
distinguishing!preMspecified!
from!exploratory!
+ Page+9+
Harms+ 19! All!important!harms!or!
unintended!effects!in!each!
group!(for!specific!guidance!
see!CONSORT!for!harms3)!
+ NA+
Discussion+ +
Limitations+ 20! Trial!limitations,!addressing!
sources!of!potential!bias,!
imprecision,!and,!if!relevant,!
multiplicity!of!analyses!
+ Pages+9,+10+
Generalisability+ 21! Generalisability!(external!
validity,!applicability)!of!the!
trial!findings!
Generalisability!to!clusters!and/or!
individual!participants!(as!
relevant)!
Page+9+
Interpretation+ 22! Interpretation!consistent!
with!results,!balancing!
benefits!and!harms,!and!
considering!other!relevant!
evidence!
+ Page+9,+10+
Other+information+ + +
Registration+ 23! Registration!number!and!
name!of!trial!registry!
+ Page+13+
Protocol+ 24! Where!the!full!trial!protocol!
can!be!accessed,!if!available!
+ The+trial+
protocol+has+
been+submitted+
with+the+
manuscript+
Funding+ 25! Sources!of!funding!and!other!
support!(such!as!supply!of!
drugs),!role!of!funders!
+ Page+2,+7+
* Note: page numbers optional depending on journal requirements 
 
 
  
 Table 2:  Extension of CONSORT for abstracts1,2 to reports of cluster randomised 
trials 
 
Item+ Standard+Checklist+item+ Extension+for+cluster+trials+
Title+ Identification!of!study!as!randomised! Identification+of+study+as+cluster+
randomised++Yes!
Trial+design+ Description!of!the!trial!design!(e.g.!parallel,!
cluster,!nonMinferiority)!
Yes+
Methods+ ! !
Participants+ Eligibility!criteria!for!participants!and!the!
settings!where!the!data!were!collected!
Eligibility+criteria+for+clusters+Yes!
Interventions+ Interventions!intended!for!each!group! !
Objective+ Specific!objective!or!hypothesis! Whether+objective+or+hypothesis+pertains+
to+the+cluster+level,+the+individual+
participant+level+or+both+Yes+
Outcome+ Clearly!defined!primary!outcome!for!this!
report!
Whether+the+primary+outcome+pertains+to+
the+cluster+level,+the+individual+participant+
level+or+both+Yes+
Randomization+ How!participants!were!allocated!to!
interventions!
How+clusters+were+allocated+to+
interventions+Yes!
Blinding+(masking)+ Whether!or!not!participants,!care!givers,!
and!those!assessing!the!outcomes!were!
blinded!to!group!assignment!
NA+
Results+ ! !
Numbers+randomized+ Number!of!participants!randomized!to!
each!group!
Number+of+clusters+randomized+to+each+
group+Yes!
Recruitment+ Trial!status1! !
Numbers+analysed+ Number!of!participants!analysed!in!each!
group!
Number+of+clusters+analysed+in+each+
group+Yes!
Outcome+ For!the!primary!outcome,!a!result!for!each!
group!and!the!estimated!effect!size!and!its!
precision!
Results+at+the+cluster+or+individual+
participant+level+as+applicable+for+each+
primary+outcome+Yes+both!
Harms+ Important!adverse!events!or!side!effects! NA+
Conclusions+ General!interpretation!of!the!results! Yes+
Trial+registration+ Registration!number!and!name!of!trial!
register!
Yes+
Funding+ Source!of!funding! Yes+
+ + +
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!
1!Relevant!to!Conference!Abstracts!
REFERENCES 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!
1  Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al.  CONSORT 
for reporting randomised trials in journal and conference abstracts. Lancet 2008, 
371:281-283 
2  Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG at al (2008) 
CONSORT for reporting randomized controlled trials in journal and conference 
abstracts: explanation and elaboration. PLoS Med 5(1): e20 
3  Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. 
Better reporting of harms in randomized trials: an extension of the CONSORT 
statement. Ann Intern Med 2004; 141(10):781-788. 
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1 INTRODUCTION 
1.1 Purpose of statistical analysis plan 
The purpose of this document is to provide details of the statistical analyses and presentation of results to 
be reported within the principal paper(s) of the RHIVA-2 trial. Subsequent papers of a more exploratory 
nature (including those involving baseline data only) will not be bound by this strategy but will be 
expected to follow the broad principles laid down in it.  Any exploratory, post-hoc or unplanned analyses 
will be clearly identified in the respective study analysis report. 
 
The structure and content of this document provides sufficient detail to meet the requirements identified 
by the International Conference on Harmonisation (ICH) and the PCTU SOP (PCTU/07).   
 
The following were reviewed in preparation for writing this document: 
Protocol version 5.0 dated 4th May 2012 
DMC report dated 27th Jan 2012 
CONSORT guidelines for the reporting of randomised trials, including extensions to cluster-
randomised trials and trials of non-pharmacological treatments  
 
1.2 Members of the writing committee 
Sally Kerry was primarily responsible for (i) writing the Statistical Analysis Strategy with Nadine Marlin 
responsible for writing the computer code implementing the analysis strategy and implementing the 
strategy at the point of analysis. A senior statistician within the Pragmatic Clinical Trials Unit (PCTU) will 
also review and sign off the final analysis strategy.  If decisions are required during the course of the 
analysis they will be discussed with a statistician within the PCTU, independent of the trial. 
 
This document has been developed prior to examination of trial data and will not be implemented prior to 
final approval.  
 
 
1.3 Summary 
The full analysis plan outlined in this document was developed prior to looking at the final databases, 
although after preparation of the DMC report for the meeting on the 1st February 2012.  The plan covers 
the analysis required to meet all primary and secondary objectives. In the event of a discrepancy the 
analyses described in the Statistical Analysis Plan will supersede those outlined in the funding application 
and the protocol. 
  ` 
1.4 Changes from planned analysis in the protocol 
The primary outcome was changed in version 4.0 (3/6/2011) to the average CD4 count in each group, 
which for presentation purposes will be converted to percentage below 200, and percentage below 350 
using the Normal distribution. The original primary outcome was the rate of HIV diagnoses in intervention 
and control surgeries. 
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2 STUDY OBJECTIVES AND ENDPOINTS 
2.1 Study objectives 
To determine whether a targeted intervention with rapid point of care testing in GP 
surgeries leads to earlier detection of HIV. 
2.1.1 Primary objectives 
To demonstrate that rapid HIV testing offered in the new patient check or at first 
consultation, when combined with an education package for healthcare professionals, 
reduces the proportion of newly diagnosed patients who present with advanced HIV 
infection An advanced HIV infection is defined as CD4 count lower than 200 cells per 
cubic millilitre of blood. This is estimated from the mean CD4 count, using a Normal 
distribution. 
2.1.2   Secondary objectives 
To demonstrate (1) a reduction in the proportion of new HIV cases that require initiation 
of HAART, defined as CD4 count less than 350 cells per cubic millilitre of blood (also 
estimated from the Normal distribution) (2) an increase in the proportion of patients newly 
diagnosed in general practice (3) an increase in the rate of standard HIV tests performed 
opportunistically including diagnostic and antenatal testing (4) a reduction in proportion of 
HIV cases with high risk of progression to AIDS, defined by a viral load of higher than 
200,000 copies per million peripheral mononuclear cells and (5) a reduction in financial 
and economic costs incurred to the PCT 
2.1.2 Exploratory objectives 
None 
2.2 Outcome measures 
2.2.1 Primary outcomes  
CD4 count of newly diagnosed patients following a GP request for HIV confirmatory 
testing at Homerton pathology. Square root transformation will be used to normalize data. 
2.2.2 Secondary outcomes 
Numbers of newly diagnosed patients in general practice 
Proportion of newly diagnosed patients in general practice 
Percentage of patients that qualify for the initiation of anti-retroviral treatment, defined as 
CD4 count lower than 350 cells per microlitre of blood, as estimated from mean CD4 count. 
Viral load. Log transformation will be used to normalize the data 
Number of HIV cases with high risk of progression to AIDS (viral load >200,000). 
Numbers of serology tests (i.e. standard HIV tests) done 
Numbers of rapid HIV tests done 
Numbers of rapid HIV tests declined 
2.2.3 Safety outcomes  
Not applicable 
3 STUDY METHODS 
3.1 Overall study design and plan 
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Target for randomisation:   40 practices 
Date of randomization:   March 2010   
Date of first random allocation: 19/04/2010 
Date of last randomisation:  01/06/2011 
Trial design:  cluster randomised, parallel group   
Blinding:    practices and researchers are unblinded     
Randomised Interventions:  intervention Vs usual care   
Allocation ratio:   1:1              
 
3.2 Selection of study population 
All practices in Hackney were invited to take part. 
 
Patients were eligible for screening if they were 16 years and older, able to undertake pre-test 
discussion in English or with suitable translator, not known to be HIV positive. 
There are two main sources of data; primary care and Homerton University Hospital including the 
Hospital pathology lab and the Department of Sexual Health (DOSH) 
 
Primary care data 
Patient data at was obtained from General Practice records for five different cohorts of patients. For 
all cohorts practice level summaries were obtained. The first cohorts record the age in categories, 
gender and ethnicity. The remainder simply record number of patients or number of tests per practice. 
Demographic cohorts 
1. All adults who were registered patients on 19/April/2010 for demographic characteristics of 
practices  
2. All patients newly registered between 19/April/2010 and 31/August /2012 
3. All patients who had at least one INSTI test result (reactive, non-reactive, indeterminate, or invalid)  
recorded between notification and 31/August 2012. 
4. All patients who had at least one INSTI test declined recorded between notification of trial 
allocation and 31/August 2012. 
5. All patients who had at least one serology test result between notification and 31/August/2012 
 
Numbers of patients per practice  
6. All patients who had at least one INSTI test result recorded between notification and 31/August 
2012. 
7. All patients who had at least one REACTIVE INSTI test result recorded between notification and 
31/August 2012. 
 
 
Number of tests per practice 
8. The number of serology test results between notification and 31/August/2012 
 
 
Homerton data 
All patients newly diagnosed with HIV  by rapid testing, opportunistic testing or antenatal testing from 
participating practices. This will be individual patient data. 
 
 
3.3 Method of treatment assignment and randomisation 
Practices were allocated to intervention or control using minimization using the following factors 
1. HIV testing rate in males April 2009 to October 2009; <7 v >=7 (testing rate is HIV male tests per 
year / male patients on list) 
2. Index of multiple deprivation of practice <47,>=47 
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3. Practice List Size <5000, 5000-7000, >=7000 
Randomisation was carried out using MINIM by Clare Rutterford (Independent PCTU statistician). 
The first 32 surgeries were allocated at once, the remaining surgeries after practice agreed to take part.  
3.4 Treatment masking (Blinding) 
Practices agreed to take part prior to allocation. 
3.5 Sample size determination  
The sample size calculations for the original study protocol were based on detecting a difference in 
the rates of HIV diagnoses between the control and intervention arms. The minimally important difference 
was 15 cases per arm per year with an expected control event rate of 21 per year; 80% power and 5% 
significance. 
  
The event rate was lower than expected and in reviewing the sample size calculations after the 
January 2011 DMC meeting, it was found the original calculations were not reproducible. Based on the 
recruitment rate to December 2010 the study could not give adequate power for a sensible minimally 
important difference. It was decided to base calculations on a measure of early diagnosis rather than 
numbers of cases. 
 
The analysis will compare mean CD4 count in the intervention and control groups. To aid 
interpretation this will be converted into the estimated numbers less than 200 and less than 350 using the 
normal distribution, based on the square root of the CD4 count. 
 
Data were obtained from the Department of Sexual Health (DOSH) at Homerton University Hospital 
for the period 1st April 2009 to 31st March 2010.  The mean CD4 count in 18 cases was 300 cells/ml (SD 
= 200). On the transformed scale, the mean was 17 and the SD 6.  The intra-cluster correlation coefficient 
(ICC) is assumed to be 0.05, a value typical in GP settings.  We assume that 20 practices will be 
randomised to screening and 20 to control. We also assume that screening practices will identify twice as 
many cases as control practices. Allowance is also made, following the method of Eldridge and Kerry 
(2006) for practices to recruit variable numbers of patients and allowing for some practices to fail 
identifying any cases (Kerry and Martin Bland, 2001; Eldridge et al., 2006). Power is 80% at the 5% 
significance level. 
Allowing for clustering, we would need to identify 48 new cases in screening practices and 23 in 
control practices in order to be able to detect an increase in the mean CD4 count from 306 to 470, which 
corresponds to a reduction in the proportion of late presenters from 30% to 10%.   
4 DATA COLLECTION 
4.1 Baseline 
Practice level 
List size 
HIV testing rate 
IMD score 
Registrants on 19/04/2010 
Proportion patients aged 16-24 
Proportion patients aged 25-34 
Proportion patients aged 35-49 
Proportion patients aged over 50 
Proportion of male patients 
Proportion of patients who were white 
Proportion of patients who were black or black British 
Proportion of patients who were Asian or Asian British 
Proportion of patients from mixed background 
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4.2 Follow up 
Please list all variables collected during follow up 
Data are collected on a number of groups of patients but these are not linked to each other 
 
From EMIS Web: 
 
New registrants in study surgeries between 19th April 2010 and August 2012 
Practice level for all practices 
Proportion patients aged 16-24 
Proportion patients aged 25-34 
Proportion patients aged 35-49 
Proportion patients aged over 50 
Proportion of male patients 
Proportion of patients who were white 
Proportion of patients who were black or black British 
Proportion of patients who were Asian or Asian British 
Proportion of patients from mixed background 
 
Patients who have an INSTI test result (reactive, non reactive, invalid, indeterminate) 
Practice level for all practices 
 
Proportion patients aged 16-24 
Proportion patients aged 25-34 
Proportion patients aged 35-49 
Proportion patients aged over 50 
Proportion of male patients 
Proportion of patients who were white 
Proportion of patients who were black or black British 
Proportion of patients who were Asian or Asian British 
Proportion of patients from mixed background 
 
Patients who have had declined an INSTI test  
Practice level for all practices 
 
Proportion patients aged 16-24 
Proportion patients aged 25-34 
Proportion patients aged 35-49 
Proportion patients aged over 50 
Proportion of male patients 
Proportion of patients who were white 
Proportion of patients who were black or black British 
Proportion of patients who were Asian or Asian British 
Proportion of patients from mixed background 
 
Patients who had serology tests 
Practice level for all practices 
 
Proportion patients aged 16-24 
Proportion patients aged 25-34 
Proportion patients aged 35-49 
Proportion patients aged over 50 
Proportion of male patients 
Proportion of patients who were white 
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Proportion of patients who were black or black British 
Proportion of patients who were Asian or Asian British 
Proportion of patients from mixed background 
 
Patients who have a INSTI test result (reactive, non reactive, indeterminate, invalid) 
Number of patients per practice 
 
Patients who have a REACTIVE INSTI test result 
Number of patients per practice 
 
Number of serology test results between notification and 31st August 2012 
 
 
From Homerton Hospital pathology lab: 
 
HIV patients from Homerton pathology 
 
There will be two sources of data;  
 
The first will contain individual patients records for patients diagnosed in primary care from 
participating practices  
 
Age 
Gender 
Ethnicity (White; Black; Asian; Mixed; Other) 
Mode of diagnosis (INSTI in new patient; INSTI non-new patient, opportunistic/diagnostic, antenatal) 
Route of acquisition (Men who have sex with men; Heterosexual; Mother to child;  intravenous drug 
user; blood products recipient; other; unknown) 
CD4 count including date 
Viral load including date 
Soundex code 
 
The second will contain numbers of patients from participating practices diagnosed during 
the study period in primary care and via other routes including the DOSH, A&E, inpatient and  
outpatient clinics and community testing sites.  
 
 
 
4.3 Timing of data collection 
Baseline practice level data has been collected at the end of the study. 
Follow up data from DOSH has been collected twice, namely at the interim analysis in January 2011 
and at the end of the study. 
Follow up demographic data from EMIS Web for 38 practices and for 2 practices using VISION will be 
downloaded at the end of the study. 
Follow up data of patients who had an INSTI test were collected on the 17th of November 2011 (April 
2010 – October 2011), and then once every 1-3 months using data collected prospectively in general 
practice over the course of the study (November 2011 to August 2012). 
Follow up data of patients who declined an INSTI test were collected on the 17th of November 2011 
(19 April 2010 – 31 October 2011), and then 1-3 monthly using data collected prospectively in general 
practice over the course of the study (01 November 2011 to 31 August 2012). 
Follow up data of patients who had a serology test result recorded have been collected at the end of 
the study. 
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5 GENERAL ISSUES FOR STATISTICAL ANALYSIS 
 All analyses will be conducted two sided and significance interpreted at the 5% significance level. 
5.1 Blinding of the statistical analysis 
The statistician analyzing the data is not blind to intervention group.  
5.2 Analysis populations 
5.2.1 Intent-to-treat population 
All practices randomized will be included in the analysis. No practices have withdrawn from data 
collection. No patients recorded on the practice computer system will be withdrawn. 
5.2.2 Available-case population 
Not applicable 
5.2.3 Per protocol population 
There will be no per protocol analysis. In the DMC report dated January 2012 a per protocol 
analysis excluding all practices who had done less than 50 tests was considered. This was not 
feasible as there were only 4 practices in this category and no patients from these practices had 
been referred to DOSH.  
5.2.4 Safety population 
Not applicable 
5.2.5 Other populations 
    Not applicable 
5.3 Database  
5.3.1 Description 
Excel 2007 was used to transfer the data from EMIS and DOSH to Stata. 
5.3.2 Data quality 
All reactive, indeterminate and invalid INSTI tests will be followed with the practice up by the research 
team and any entry errors corrected. 
 
Data from DOSH patients was extracted by one of the HIV consultants (JA) from DOSH hospital 
records and checked by two GP investigators (CG, WL). Checks are made on accuracy of entered 
data and completeness and eligibility of patient sample. A randomly selected 20% check was carried 
out by an independent external monitor (Adrian Martineau). 
 
Once the trial team have completed all data entry and checking, the statistician will merge practice 
level data with individual patients level data and check any non-matching records. There will be 4 final 
data files;  
 
1. Patient level data for INSTI tests with minimisation factors 
2. Patient level data for HIV serology tests with minimisation factors 
3. Practice level data from DOSH with minimisation factors 
4. All practice level data 
 
All variables will be tabulated (and cross tabulated where appropriate) and range of values verified. 
Notes column will be checked on DOSH data to ensure all patients are eligible and known positives 
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are excluded. Dates will be checked to ensure they are post allocation of the practice and prior to 31st 
August 2012.   
 
Once any discrepancies have been dealt with the databases will be locked for analysis.  This means 
that the database will be made read-only.  If during the analysis unforeseen queries are generated 
they will be dealt with on a case-by-case basis.  Any subsequent changes to the data can be made 
but will be recorded and reported. 
5.4 Analysis software 
The analysis will be carried out using Stata version 12. 
5.5 Methods for withdrawals, loss to follow-up and missing data  
Withdrawals and loss to follow up of patients is not applicable. No practices are lost to follow up. 
Data may be missing for CD4 counts and viral load but the data is too sparse for multiple imputation 
methods.  
5.6 Method for handling centre effects 
Not applicable 
5.7 Method for handling minimisation factors 
Analysis will be carried out adjusting for minimisation factors 
5.8 Method for handling clustering effects 
The small number of clusters and units within cluster including a high percentage of singleton clusters 
suggests using a mixed model approach allowing a random effect for practice. Bell(2008) and 
Clarke(2007) both describe that the coefficients should be unbiased using this approach whereas the 
error terms including the confidence intervals will likely be biased. Any potential modeling results will be 
interpreted with caution. 
5.9 Method for selecting other variables that will be adjusted for 
None 
5.10 Multiple comparisons and multiplicity 
Not taken into account. CD4 count is the main outcome measure; there are only three other 
secondary outcome measures 
5.11 Method for handling non-adherence  
Not applicable 
5.12 Method for handling time-varying interventions 
Not applicable 
5.13 Method for handling outliers 
None 
5.14 Derived and computed variables 
All derived and computed variables will be documented in the analysis programs. 
 
Ethnicity data from practices will be classified as follows 
White      
Black    
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Asian  
Mixed race    
Other  
 
These correspond to the main headings for the data collected from DOSH but EMIS collects data in 
more detailed form. A classification list is in Appendix 2.    
 
Viral load has a lower limit of 40. Since only a very small proportion of patients are expected to have 
a viral load <40 it will be replaced by 40 in the analysis. A sensitivity analysis will be performed excluding 
values below 40. 
Square root transformation of CD4 count used in analysis 
Log of viral load used in the analysis 
6 DESCRIPTIVE ANALYSES 
6.1 Participant flow 
Practice and Participant throughput will be summarized in a CONSORT diagram. 
Template in Appendix 3 
6.2 Representativeness of sample 
Number of practices who declined to take part will be reported 
Practice characteristics for those taking part will be described; age, sex, ethnicity and IMD score. 
These will be compared with Hackney as a whole and London as a whole. 
6.3 Baseline comparability of randomised groups 
6.3.1 Demographics 
Age groups, sex and ethnicity will be tabulated by intervention arm (Appendix 4 table 1) 
6.3.2 Prior and concurrent medications 
Not applicable 
6.3.3 Baseline and screening conditions 
Not applicable 
6.3.4 Baseline medical history 
Not applicable 
6.3.5 Baseline physical exam 
Not applicable 
6.3.6 Cluster characteristics if cluster randomized 
For all characteristics the proportions will calculated across all practices i.e. equal weight to each 
patient not each practice. The range between practices will be given. 
Practice list size at time of minimisation 
IMD score 
Male HIV testing rate at minimization 
6.3.7 Characteristics of care providers where applicable 
Not applicable 
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6.4 Comparison of losses to follow-up 
Not applicable 
6.5 Comparison of compliance to treatment and protocol 
Comparison of practices who have withdrawn from the intervention with those continuing 
 
Number of practices 
Percentage in age groups (weighted by practice size) 
Percentage female, range (weighted by practice size) 
Percentage White, Black, Asian, Mixed ,range (weighted by practice size) 
Number of newly registered patients  
 
6.6 Emergency or accidental unblinding of randomised treatment 
Not applicable 
7 INTERIM ANALYSES AND SAFETY MONITORING ANALYSES 
7.1 Purpose of interim analyses 
An effectiveness analysis was carried out 6 months after the start of the trial and in view of the low 
recruitment rate a further analysis was carried out after 18 months. The purpose of the analysis was to 
ensure the trial was still in equipoise and to review the sample size calculations.  
 
7.2 Monitoring plan 
Data was extracted up to 31st December prior to the DMC meeting. 
The interim analysis was carried out prior to DMC meetings in January 2011 and February 2012.   
7.3 Stopping rules 
The DMC charter states the p-value for consideration of stopping to be <0.001 
7.4 Measures taken to minimize bias 
Low p-value stated for stopping the trial. 
7.5 Adjustment for p-values 
Not applicable 
7.6 Interim analysis for sample size adjustment 
The sample size calculations were revised in May 2011 (Protocol version 4.0). This was based on the 
numbers of cases diagnosed up to December 2010, using data from the DOSH. 
8 ANALYSIS OF PRIMARY OUTCOME 
8.1 Definition of outcome measure 
The primary outcome is CD4 count obtained from the DOSH. This will be transformed with a square 
root transformation prior to analysis. 
8.2 Descriptive statistics for outcome measure 
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Mean and SD of the raw data and the transformed data will be given for intervention and control 
groups, without adjusting for clustering 
8.3 Primary analysis 
• The primary analysis pertains to the individual rather than the cluster. 
• The square root of the CD4 will be compared between intervention and control, allowing for 
clustering effect of practices in the mixed model and adjusting for minimisation factors. 
• Following analysis the relative risk for the percentage with CD4 could below 200 and below 350 
will be estimated using the methods of Peacock et al 2012. 
• The iccs will be calculated using analysis of variance methods. If the ICC estimates are negative 
analysis will be carried out ignoring the clustering.  
8.4 Assumption checks 
The distribution of CD4 count before and after transformation will be assessed by examination of 
using normal plots, SD and histograms of the data. The square root transformation will be used unless 
there is strong evidence to the contrary.  
8.5 Other analysis supporting the primary (inc. sensitivity analyses) 
The following sensitivity analyses will be carried out:  
1. Analyses of primary and secondary outcomes, EXCLUDING patients diagnosed through 
antenatal testing. 
2. Analyses of primary and secondary outcomes, EXCLUDING patients with CD4 count <40 
3. Analyses of primary and secondary outcomes to include all patients diagnosed with HIV in 
general practice, whether or not there is a previous record of an HIV diagnosis and WHERE 
THE PATIENT HAS DEFAULTED CARE (IE >12m). 
 
Rationale for 3: Some patients who test positive for HIV either do not access care, or access care and 
default or are lost to follow up. For such patients, a further positive test can lead to them re-accessing 
care, with potential beneficial health outcomes. We want to quantify this aspect of HIV diagnosis and ‘re-
diagnosis’, recognizing that a prior diagnosis introduces a delay which will affect CD4 and viral load 
counts. The primary analysis excludes patients with a prior positive HIV test (data available from the 
HPA). We therefore will carry out the above sensitivity analysis to include those with a prior positive test 
but who have defaulted care. 
 
9 ANALYSIS OF SECONDARY OUTCOMES 
9.1 Definition of outcome measure 
1. Numbers of newly diagnosed patients in general practice 
The number of patients diagnosed will be obtained from Homerton records. The rate of diagnosis per 
1,000 patients per year will be estimated using the time the practice has been in the study since allocation 
to intervention arm and the list size at randomization.  
  
2. Proportion of newly diagnosed patients in general practice 
This is the number of patients diagnosed in each practice through primary care as a percentage of all 
patients diagnosed in each practice either through primary or secondary care (Data source: DOSH).  
 
3. Viral load 
The log transformation of the viral load will be compared between intervention and control, adjusting 
for clustering using the cluster option and adjusting for minimisation factors. 
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9.2 Descriptive statistics for outcome measure 
For the intervention and control groups the following data will be presented for the period of the 
intervention 
Number of patients registered on 19/April/2010 
Number of newly registered patients 
Number of HIV (BROKEN DOWN BY INSTI TESTS AND SEROLOGY TESTS) tests done  
Number of HIV (BROKEN DOWN BY INSTI TESTS AND SEROLOGY TESTS) tests done as a 
percentage of baseline list size and range 
Numbers newly diagnosed in general practice and rate of diagnosis per 1,000 patients and range./ 
Number of practices who have diagnosed at least one case 
 
Mean (SD) CD4 count 
Mean (SD) Square root of CD4 count 
Intervention effect for CD4 count with 95% confidence interval 
 
Mean (SD) viral load 
Mean (SD) Log of viral load 
Intervention effect for viral load with 95% confidence interval back transformed 
 
9.3 Secondary analysis 
The secondary analysis pertains to the individual rather than the cluster. 
 
1. Numbers of newly diagnosed patients in general practice  
The intervention effect will be calculated using a regression model on the log of the rate for each 
practice, adjusting for clustering. To allow practices who fail to diagnose a patient 0.01 will be added 
to the number of cases for each practice prior to log transformation. The results will be presented at 
the rate of diagnosis for all practices in each intervention arm and the adjusted rate ratio between 
intervention and control arms. 
 
2. Proportion of newly diagnosed patients in general practice 
This will be analysed using a mixed effects logistic regression model allowing for clustering and 
minimization factors  
 
9.4 Assumption checks 
The analysis adjusts for minimisation factors. This is the recommended approach and should lead to 
more precise estimation of the intervention effect. However if the rate ratio of the diagnoses varies 
between minimisation factors the intervention effect may be underestimated, because the patients in the 
intervention group practices with the characteristics associated with more cases are down weighted. 
 
The following analysis explores this hypothesis 
  
CD4 count will be analysed without adjustment for minimization factors. 
 
A comparison of the number of cases diagnosed for each minimization factor will be investigated to 
see if the intervention effect appears constant across all factors. Intervention effect will be measured 
using the rate ratio. 
If the rate ratio is not constant then adjusting for minimization factors may weaken the observed effect 
of the intervention.  
This may be reported as an exploratory analysis 
9.5 Other analysis supporting the secondary (inc. sensitivity analyses) 
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The implementation of the intervention 
Within the intervention arm the following will be reported 
Mean number per practice (range) of rapid tests offered 
Mean number per practice (range) rapid tests done 
Mean number per practice (range) SEROLOGY tests done 
Mean number per practice (range) ALL (i.e. rapid AND SEROLOGY) tests done 
 
 
Number of true rapid reactive tests and number of practice contributing to true reactive tests  
10 AMENDMENTS FROM THE PROTOCOL 
Analysis for the following  secondary outcomes will not be performed. 
• Clade and genotype of the virus at the time of diagnosis as predictors of disease progression 
This is due to the data not being collected. 
11 AMENDMENTS TO VERSION 1.0 
This is the first version of the analysis plan 
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